Mucin-binding protein shuttles for the delivery of brain-targeted therapeutics
Patent Information
- Application Number
- PCT/US2026/023457
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-04-11
- Filing Date
- 2026-04-13
- Publication Date
- 2026-11-12
AI Technical Summary
The blood-brain barrier (BBB) poses a significant challenge for delivering therapeutics to the brain due to its selective barrier properties, limiting the entry of most therapeutics, including small and larger molecules, and existing methods like intracranial delivery are invasive and have limited biodistribution.
Mucin-binding protein shuttles that target mucin-domain glycoproteins on brain endothelial cells, utilizing a caveolae-dependent endocytic pathway for non-invasive, systemic delivery of cargo molecules across the BBB, including therapeutic and diagnostic agents.
Facilitates efficient delivery of diverse molecular cargo, including therapeutic agents, into brain cell types such as neurons, astrocytes, and microglia, offering an alternative to conventional receptor-mediated transcytosis strategies.
Smart Images

Figure US2026023457_12112026_PF_FP_ABST
Abstract
Description
STDU2-44870.601MUCIN-BINDING PROTEIN SHUTTLES FOR THE DELIVERY OF BRAIN- TARGETED THERAPEUTICS
[0001] The present application claims priority to United States Provisional Patent Application Serial Number 63 / 787,430, filed April 11, 2025, the disclosure of which is herein incorporated by reference in its entirety.SEQUENCE LISTING
[0002] The text of the computer readable sequence listing filed herewith, titled “STDU2-44870-601_SQL.xml”, created April 8, 2026, having a file size of 18,767 bytes, is hereby incorporated by reference in its entirety.TECHNICAL FIELD
[0003] Disclosed herein are methods and compositions that are able to mediate transport of payloads across the blood-brain barrier (BBB) and methods and compositions for the transport of payloads across the BBB.BACKGROUND
[0004] The development of therapeutics for neurological and neurodegenerative diseases has long been hindered by the inability to effectively deliver therapeutics across the brain vasculature, which forms a highly selective barrier between the blood and brain, known as the blood-brain barrier (BBB). The BBB constitutes a physical barricade that is formed by brain endothelial cells (BECs) that line the blood vessels and connect with each other through tight junctions (Abbott, 2013). The tight junctions formed between the BECs are essential for the integrity of the BBB and prevent the paracellular transport of hydrophilic molecules larger than 500 daltons (Da). Because brain endothelial cells exhibit very low pinocytosis rates (Abbott, 2013), transcellular transport of larger molecules is limited to the highly specific receptor mediated transcytosis (RMT) pathway, and the passive, charge-based adsorption mediated transcytosis (Abbott, 2013; Pardridge, 2002). While all these characteristics protect the brain from pathogens and toxins, they equally prevent the entry of most therapeutics. In fact, less than 5% of small molecule therapeutics and virtually none of the larger therapeutics can cross the BBB in pharmacologically relevant concentrationsSTDU2-44870.601(i.e., sufficient to engage a central nervous system (CNS) target and elicit pharmacologic / therapeutic response) unless they are specifically “ferried,” that is, coupled to a transporter molecule. Due to the lack of effective carriers to transport molecules across the BBB, numerous drugs against neurodegenerative diseases have been shelved or eliminated from further development as they cannot be delivered to the brain in sufficient amount.
[0005] Moreover, many existing drug administration methods that circumvent the BBB, such as intracranial, intrathecal, or intraventricular delivery, are highly invasive and exhibit limited biodistribution. As a result, strategies that facilitate systemic drug delivery across the BBB are of significant interest. Many new approaches are being developed to more effectively deliver therapeutics across the BBB, including the use of endogenous receptor-mediated transport (RMT) receptors, such as the transferrin and insulin receptors, which are endogenously internalized by brain endothelial cells and can transport associated cargo1,2.SUMMARY OF THE INVENTION
[0006] The present disclosure provides mucin-binding protein shuttles and conjugates thereof that exploit the cerebrovascular glycocalyx as a novel entry pathway for delivering cargo molecules across the blood-brain barrier (BBB). By targeting mucin-domain glycoproteins abundantly expressed on the luminal surface of brain endothelial cells, these shuttles facilitate efficient, noninvasive, systemic delivery of diverse molecular cargo into the brain, including delivery into key brain cell types such as neurons, astrocytes, and microglia. The shuttles operate through a mechanistically distinct caveolae-dependent endocytic pathway, offering an alternative and complementary approach to conventional receptor-mediated transcytosis strategies. The present disclosure further provides methods of using these shuttles for brain delivery of therapeutic, diagnostic, and other cargo molecules, as well as nucleic acids, expression systems, pharmaceutical compositions, and kits related thereto.
[0007] In one aspect, the present disclosure provides a conjugate comprising a mucin-binding protein or a mucin-binding fragment thereof operably linked to a cargo molecule, wherein the mucin-binding protein or mucin-binding fragment thereof is capable of binding to a mucin-domain glycoprotein on the surface of a brain endothelial cell and mediating internalization of the cargo molecule into the brain endothelial cell.STDU2-44870.601
[0008] In some embodiments, the mucin-binding protein or mucin-binding fragment thereof mediates internalization via a caveolae-dependent endocytic pathway.
[0009] In some embodiments, the mucin-binding protein or mucin-binding fragment thereof mediates transport of the cargo molecule across the blood-brain barrier.
[0010] In some embodiments, the mucin-binding protein or mucin-binding fragment thereof is derived from a bacterial mucinase or an enzymatically inactive variant thereof. In certain such embodiments, the bacterial mucinase is secreted protease C (StcE) from Escherichia coli or an ortholog thereof.
[0011] In some embodiments, the mucin-binding protein comprises an amino acid sequence having at least about 70% sequence identity to SEQ ID NO: 1. In further embodiments, the mucinbinding protein comprises an amino acid sequence having at least about 80%, at least about 90%, at least about 95%, or 100% sequence identity to SEQ ID NO:1.
[0012] In some embodiments, the mucin-binding fragment comprises the C-terminal domain of StcE or an enzymatically inactive variant thereof.
[0013] In some embodiments, the mucin-binding fragment comprises an amino acid sequence having at least about 70% sequence identity to SEQ ID NO:2. In further embodiments, the mucinbinding fragment comprises an amino acid sequence having at least about 80%, at least about 90%, at least about 95%, or 100% sequence identity to SEQ ID NO:2. In certain embodiments, the mucin-binding fragment consists essentially of the amino acid sequence of SEQ ID NO:2. In some embodiments, the mucin-binding fragment has a molecular weight of about 15 kDa or less.
[0014] In some embodiments, the mucin-binding protein is a truncated variant of SEQ ID NO: 1 comprising the C-terminal domain and lacking one or more domains selected from the group consisting of the immunoglobulin-like (IG) domain, the insertion (INS) region, and the metalloprotease (M) domain. In certain such embodiments, the truncated variant lacks the INS region and comprises the IG domain, the M domain, and the C-terminal domain. In other embodiments, the truncated variant consists essentially of the C-terminal domain.
[0015] In some embodiments, the mucin-binding fragment comprises a contiguous amino acid sequence of at least 50 amino acid residues of SEQ ID NO:2 and retains mucin-dependent binding and internalization activity. In further embodiments, the mucin-binding fragment comprises at least about 70% or at least about 80% of the amino acid residues of SEQ ID NO:2.STDU2-44870.601
[0016] In some embodiments, the mucin-binding protein or mucin-binding fragment thereof comprises the amino acid sequence of SEQ ID NO:1 or SEQ ID NO:2 with 1 to 20 amino acid substitutions, and wherein the mucin-binding protein or mucin-binding fragment thereof retains mucin-dependent binding and internalization activity. In certain such embodiments, the amino acid substitutions are conservative amino acid substitutions. In further embodiments, the mucin-binding protein or mucin-binding fragment thereof comprises 1 to 10 amino acid substitutions, or 1 to 5 amino acid substitutions.
[0017] In some embodiments, the cargo molecule is selected from the group consisting of a protein, a peptide, an antibody or antigen-binding fragment thereof, an enzyme, a growth factor, a cytokine, a hormone, a nucleic acid, a small molecule, a nanoparticle, a liposome, a viral vector, a detectable label, and a diagnostic agent.
[0018] In some embodiments, the cargo molecule is a detectable label selected from the group consisting of a fluorescent protein, a fluorescent dye, a radioactive isotope, a paramagnetic agent, a contrast agent, a quantum dot, and an enzyme that produces a detectable signal.
[0019] In some embodiments, the cargo molecule is a diagnostic agent capable of binding to, detecting, or imaging a target molecule in the brain.
[0020] In some embodiments, the cargo molecule is a protein having a molecular weight of at least about 10 kDa.
[0021] In some embodiments, the cargo molecule is a therapeutic agent. In certain such embodiments, the therapeutic agent is an antibody or antigen-binding fragment thereof. In further embodiments, the antibody or antigen-binding fragment thereof is selected from the group consisting of a monoclonal antibody, a humanized antibody, a fully human antibody, a bispecific antibody, a single-chain variable fragment (scFv), a Fab fragment, a F(ab')2 fragment, a singledomain antibody, and a nanobody. In still further embodiments, the antibody or antigen-binding fragment thereof specifically binds to a target selected from the group consisting of BACE1, amyloid beta, tau, alpha-synuclein, TDP-43, huntingtin, SOD1, PD-L1, CD20, HER2, EGFR, VEGF, and a tumor-associated antigen expressed in the central nervous system. In a particular embodiment, the antibody or antigen-binding fragment thereof is an anti-BACE1 antibody.
[0022] In some embodiments, the therapeutic agent is a lysosomal protein. In certain such embodiments, the lysosomal protein is progranulin or a functional fragment thereof.STDU2-44870.601
[0023] In some embodiments, the therapeutic agent is selected from the group consisting of an enzyme replacement therapy protein, a neurotrophic factor, an anti-inflammatory agent, a chemotherapeutic agent, and a gene therapy vector.
[0024] In some embodiments, the therapeutic agent is an adeno-associated virus (AAV) vector comprising a transgene encoding a therapeutic protein.
[0025] In some embodiments, the therapeutic agent is a nucleic acid selected from the group consisting of an antisense oligonucleotide, a small interfering RNA (siRNA), a short hairpin RNA (shRNA), a microRNA, a messenger RNA (mRNA), a guide RNA, and a ribonucleoprotein complex.
[0026] In another aspect, the present disclosure provides a pharmaceutical composition comprising any of the conjugates described herein and a pharmaceutically acceptable carrier. In some embodiments, the pharmaceutical composition is formulated for intravenous administration.
[0027] In another aspect, the present disclosure provides a method for delivering a cargo molecule across the blood-brain barrier of a subject, comprising administering to the subject a conjugate comprising a mucin-binding protein or a mucin-binding fragment thereof operably linked to the cargo molecule, wherein the mucin-binding protein or mucin-binding fragment thereof binds to a mucin-domain glycoprotein on the surface of a brain endothelial cell and mediates transport of the cargo molecule across the blood-brain barrier.
[0028] In some embodiments, the conjugate is administered systemically. In certain such embodiments, the conjugate is administered intravenously.
[0029] In some embodiments, the cargo molecule is delivered to one or more brain cell types selected from the group consisting of brain endothelial cells, neurons, astrocytes, and microglia.
[0030] In some embodiments, the cargo molecule is delivered across multiple brain regions.
[0031] In some embodiments, the cargo molecule is a detectable label or a diagnostic agent, and the method is for imaging or detecting a target in the brain.
[0032] In some embodiments, the conjugate administered in the foregoing methods comprises any of the conjugates described herein.
[0033] In another aspect, the present disclosure provides an isolated nucleic acid encoding a fusion protein comprising a mucin-binding protein or a mucin-binding fragment thereof fused to a cargo protein, wherein the mucin-binding protein or mucin-binding fragment thereof comprises anSTDU2-44870.601amino acid sequence having at least about 70% sequence identity to SEQ ID NO:1 or SEQ ID NO:2.
[0034] In another aspect, the present disclosure provides an expression vector comprising any of the foregoing nucleic acids operably linked to a promoter.
[0035] In another aspect, the present disclosure provides a host cell comprising any of the foregoing expression vectors. In some embodiments, the host cell is selected from the group consisting of a bacterial cell, a yeast cell, an insect cell, and a mammalian cell.
[0036] In another aspect, the present disclosure provides a method of producing a conjugate for brain delivery, comprising culturing any of the foregoing host cells under conditions sufficient for expression of the fusion protein and recovering the fusion protein from the host cell or culture medium.
[0037] In another aspect, the present disclosure provides a kit comprising: (a) a mucin-binding protein or a mucin-binding fragment thereof comprising an amino acid sequence having at least about 70% sequence identity to SEQ ID NO:1 or SEQ ID NO:2; and (b) a linker or conjugation reagent for operably linking the mucin-binding protein or mucin-binding fragment to a cargo molecule of interest. In some embodiments, the kit further comprises instructions for conjugating the mucin-binding protein or mucin-binding fragment to a cargo molecule and administering the resulting conjugate to a subject.
[0038] In another aspect, the present disclosure provides the use of a conjugate comprising a mucin-binding protein or a mucin-binding fragment thereof operably linked to a cargo molecule for the delivery of the cargo molecule across the blood-brain barrier, wherein the mucin-binding protein or mucin-binding fragment thereof binds to a mucin-domain glycoprotein on the surface of a brain endothelial cell. In some embodiments, the mucin-binding fragment comprises an amino acid sequence having at least about 70% sequence identity to SEQ ID NO:2.
[0039] In yet another aspect, the present disclosure provides the use of a conjugate comprising a mucin-binding protein or a mucin-binding fragment thereof operably linked to a therapeutic agent in the manufacture of a medicament for the treatment of a neurological disease or condition, wherein the mucin-binding protein or mucin-binding fragment thereof mediates transport of the therapeutic agent across the blood-brain barrier.BRIEF DESCRIPTION OF THE DRAWINGSSTDU2-44870.601
[0040] Figs. 1(a-i) provide data demonstrating that Glycocalyx-targeting probes facilitate cellular internalization, a) Diagram of cell surface glycocalyx components that may serve as GlycoShuttle targets, b) Cellular internalization assay to evaluate the capacity of fluorescently labeled glycocalyx-targeting probes to bind and enter bEnd.3 cells, c) Quantification of the mean fluorescence intensity (MFI) of fluorescein in cells normalized by the degree of labeling (DOL) of glycocalyx-binding probes (n=3 wells per construct; one-way ANOVA with Dunnett’s post hoc test; mean ± s.e.m.). d) Representative images of cellular binding and internalization of glycocalyx-binding probes after 30-min incubation with bEnd.3 cells. Scale bar=25 μm. e) SMS 1 shuttles mCherry cargo into bEnd.3 cells in a mucin-dependent manner. Pre-treatment of cells with StcE mucinase for 1 h removes cell surface mucins (5, 8) and abolishes SMS1 binding and internalization. Scale bar=25 μm. f) Quantification of mCherry MFI in (e) (n=4 wells per construct; one-way ANOVA with Dunnett’s post hoc test; mean ± s.e.m ). g) mCherry-SMS1 colocalization with caveolin-1 (CAV1) and clathrin heavy chain (CLTC) in bEnd.3 cells with average Pearson correlation coefficient (r) displayed. Colocalization threshold mask in grayscale. Scale bar=10 μm. h) Colocalization of mCherry-StcEE447D with various subcellular compartments measured by Pearson correlation coefficient (n=4 wells per compartment; mean ± s.e.m.). i) Schematic depicting the model of SMS internalization into brain endothelial cells. SMS binds mucins on the surface of brain endothelial cells, leading to internalization of SMS and any attached cargo in cholesterol-rich microdomains, or lipid rafts, via caveolae-mediated endocytosis. Cargo can then be trafficked via the endolysosomal pathway or transcytosed.
[0041] Figs. 2(a-g) provide data showing that SMS1 (StcEE447D) can be used as a shuttle to traffic cargo into neurons, microglia and astrocytes in mice, a) Experimental setup for measuring brain uptake of mCherry-SMS 1 into different cell types via flow cytometry, confocal imaging, and ELISA, b) mCherry MFI in brain endothelial cell (BEC) (CD31+ ) and non-BEC (CD31- ) populations as measured by flow cytometry at 24 h and 48 h after 5 mg / kg i.v. injection of mCherry-SMS 1 or an equimolar dose of unconjugated mCherry (n=3 mice per group; one-way ANOVA with Dunnett’s post hoc test; mean ± s.e.m.). c) mCherry-SMS 1 internalization into the cortex at 2, 6, and 24 h after 5 mg / kg i.v. injection compared to unconjugated mCherry internalization at 24 h. Scale bar=50 μm. d) mCherry-SMS 1 internalization outside of the vasculature at 24 h after 5 mg / kg i.v. injection. Scale bar=10 μm. e) Microglial uptake of mCherry -SMS1. Scale bar=25 μm (left) and 5 μm (right). f) Neuronal uptake of mCherry-SMS 1. ScaleSTDU2-44870.601bar=25 pm (left) and 5 pm (right), g) Astrocytic uptake of mCherry-SMS1. Scale bar=25 μm (left) and 5 μm (right).
[0042] Figs. 3(a-j) provide data demonstrating that the C domain is necessary and sufficient for SMS1 internalization into the brain, a) AlphaFold generated structure of mCherry-SMS1. b) mCherry-SMS1 mutant constructs used in internalization assays. Domain boundaries and nomenclature follow Yu A. C. Y, et al. (17). Color-coded regions include: mCherry (pink), flexible linker (gray), immunoglobulin-like domain (IG; orange), insertion region (INS; yellow), metalloprotease domain (M; green), additional disordered regions (D; cyan), and C-terminal domain (C; blue). The N-terminal His tag is omitted. Amino acid positions are indicated, c) Binding and internalization of mCherry-SMS1, mCherry-SMS IDINS, mCherry-SMS1DC, mCherry-SMS2, and mCherry in bEnd.3 cells after 30-min incubation at 37°C. Scale bar=25 μm. d) Quantification of (c) (n=3 wells per construct; one-way ANOVA with Dunnett’s post hoc test; mean ± s.e.m.). e) Internalization of mCherry-SMS1, mCherry-SMS IDINS, mCherry-SMS1DC, mCherry-SMS2, and mCherry into the cortex at 24 h after i.v. injection of 5 mg / kg mCherry-SMS1 or molar equivalents of mutant constructs, f) ELISA quantification of mCherry in brain hemisphere tissue from mice treated with mCherry, mCherry-SMS 1, or mCherry-SMS2 (n=4 animals per construct; one-way ANOVA with Tukey’s post hoc test; mean ± s.e.m.). g) ELISA quantification of mCherry in the vascular fraction of brain tissue from mice treated with mCherry, mCherry SMS1, or mCherry-SMS2 (n=4 animals per construct; one-way ANOVA with Tukey’s post hoc test; mean ± s.e.m.). h) ELISA quantification of mCherry in the parenchymal fraction of brain tissue from mice treated with mCherry, mCherry-SMS 1, or mCherry-SMS2 (n=4 animals per construct; one-way ANOVA with Tukey’s post hoc test; mean ± s.e.m.). i) Flow cytometry analysis of mCherry-SMS2 uptake by neurons, microglia, and brain endothelial cells compared to unconjugated mCherry (n=4 animals per construct; two-sided t-test; mean ± s.e.m.). j) Plasma PK analysis of mCherry, mCherry-SMS 1, and mCherry-SMS2-injected mice over 24 hours (n=4 animals per construct; two-way ANOVA with Dunnett’s post hoc test; mean ± s.e.m.).
[0043] Figs. 4(a-i) provide data demonstrating that the C domain (SMS2) facilitates widespread delivery of anti-BACE1 antibody into the brain and reduces amyloidogenic A production, a) αBACE1 and αBACE1-SMS2 constructs used in this study, b) Binding and internalization of αBACE1 and αBACE1-SMS2 in bEnd.3 cells. Scale bar=25 μm. c) Quantification of binding and internalization of αBACE1 and αBACE1-SMS2 in bEnd.3 cells (n=4STDU2-44870.601wells per construct; one-way ANOVA with Sidak’s post hoc test; mean ± s.e.m.). Binding and internalization of αBACE1-SMS2 is dependent on cell surface mucins, d) hlgG immunofluorescence staining of mouse brains 48 hours after a single intravenous dose of saline, αBACE1 antibody, or αBACE1-SMS2 at equimolar dosing (equivalent to 25 mg / kg αBACE1-SMS2). Scale bar=1 mm. e) Experimental scheme comparing internalization and therapeutic efficacy of αBACE1 versus αBACE1-SMS2 treatment in 5XFAD mice, f) ELISA quantification of hlgG internalization in the brains of 5XFAD mice treated with αBACE1 or αBACE1-SMS2 48 hours after treatment (n=4-5 animals per construct; two-sided t-test; mean ± s.e.m.). g) ELISA quantification of Aβ42 levels in the brains of 5XFAD mice treated with αBACE1 or αBACE1-SMS2 48 hours after treatment (n=4-5 animals per construct; two-sided t-test; mean + s.e.rn.). h) Plasma PK analysis of A 42 levels in mice treated with αBACE1 or αBACE1-SMS2 over 24 hours (n=4 animals per construct; two-way ANOVA with Dunnett’s post hoc test; mean ± s.e.m.). i) Plasma PK analysis of A 4O levels in mice treated with αBACE1 or αBACE1-SMS2 over 24 hours (n=4 animals per construct; two-way ANOVA with Dunnett’s post hoc test; mean ± s.e.m.).
[0044] Figs 5(a-f) provide data demonstrating that SMS2 facilitates brain delivery of progranulin into the brain and improves rescue of lysosomal lipid dysregulation in GRN-deficient mice, a) Diagram of hPGRN and SMS2-hPGRN protein constructs, b) hPGRN and SMS2-hPGRN constructs used in this study. Highlighted regions include a GGS linker (dark gray), progranulin (blue), and SMS2 module (purple). Amino acid positions are indicated, c) Binding and internalization of hPGRN and SMS2-hPGRN in bEnd.3 cells. Binding and internalization of SMS2-hPGRN is dependent on cell surface mucins. Scale bar=25 μm. d) Quantification of hPGRN MFI in (c) (n=3 wells per construct; one-way ANOVA with Sidak’s post hoc test; mean ± s.e.m.). e) Experimental scheme for Grn- / - mice treatment with saline, hPGRN, or SMS2-hPGRN at equimolar dosing (equivalent to 15 mg / kg SMS2-hPGRN) for 48 h. f) BMP quantification in brains of Grn- / - mice treated with saline, hPGRN, or SMS2-hPGRN, with key altered BMP species shown (n=5 animals per group; two-way ANOVA with Tukey’s post hoc test; mean ± s.e.m.).
[0045] Figs 6 (a-g) provide characterization of GlycoShuttle constructs, a) Properties of glycocalyx-binding proteins tested including quaternary structure, molecular weight (MW), isoelectric point (pl), and glycan specificity (9). b) SMS1 shuttles mCherry cargo into human primary brain endothelial cells. Scale bar=25 μm. c) Anti-TfRl (8D3) internalization into bEnd.3STDU2-44870.601cells is unaffected by StcE-mediated mucin removal. Scale bar=25 μm. d) Quantification of anti-TfR.1 MFI in (c) (n=4 wells per construct; two-sided t-test; mean ± s.e.m.). e) Treatment of bEnd.3 cells with bafilomycin increases mCherry-SMS1 punctate signal. Scale bar=25 μm. f) Quantification of mCherry MFI in (e) (n=4 wells per construct; two-sided t-test; mean ± s.e.m.). g) Treatment of bEnd.3 cells with caveolae / lipid raft inhibitors perturbs mCherry-SMS1 binding and internalization into cells. Scale bar=25 μm.
[0046] Fig. 7(a-e) provide data demonstrating that SMS1 (StcEE447D) is endocytosed via a caveolae-dependent pathway in brain endothelial cells, (a) mCherry-StcEE447Dcolocalization with caveolin-1 (CAV1) and clathrin heavy chain (CLTC) in bEnd.3 cells, (b) Colocalization of mCherry-StcEE447Dwith various subcellular compartments using Pearson correlation (n=2-4 wells per compartment; mean ± s.e.m.). (c) Pre-treatment of bEnd.3 cells with caveolae inhibitors reduces mCherry- StcEE447Dbinding and internalization into cells, whereas pre-treatment of bEnd.3 cells with non-caveolae endocytosis inhibitors does not reduce mCherry-StcEE447Dbinding / intemalization in bEnd.3 cells. Scale bar=25 μm for caveolae inhibitors and 50 μm for non-caveolae inhibitors, (d) Quantification of mCherry- StcEE447Dbinding and internalization in bEnd.3 cells in the presence of different endocytosis inhibitors (n=2-4 wells per group; two-sided t-test; mean ± s.e.m.). (e) Schematic depicting the current understanding of the mechanism of mCherry- StcEE447Dinternalization into brain endothelial cells. StcEE447Dbinds mucins on the surface of brain endothelial cells, leading to internalization of StcEE447Dand any attached cargo via caveolae -mediated endocytosis. Cargo can then be trafficked via the endolysosomal pathway or transcytosed.
[0047] Figs 8(a-f) provide data demonstrating mCherry-StcEE447Dinternalization into peripheral organs, a) Representative liver sections showing distribution of mCherry, mCherry-SMS1, and mCherry-SMS2 at 48 hours following equimolar dosing (equivalent to 5 mg / kg mCherry-SMS l). Scale bar=50 μm. b) Quantification of relative mCherry MFI in (a) (n=4 animals per construct; one-way ANOVA with Tukey’s post hoc test; mean ± s.e.m.). c) Representative heart sections showing distribution of mCherry, mCherry-SMS1, and mCherry-SMS2 at 48 hours following equimolar dosing (equivalent to 5 mg / kg mCherry- SMS 1). Scale bar=50 μm. d) Quantification of relative mCherry MFI in (c) (n=4 animals per construct; one-way ANOVA with Tukey’s post hoc test; mean ± s.e.m.). e) Representative kidney sections showing distribution of mCherry, mCherry-SMS1, and mCherry-SMS2 at 48 hours following equimolar dosingSTDU2-44870.601(equivalent to 5 mg / kg mCherry-SMS 1). Scale bar=50 μm. f) Quantification of relative mCherry MFI in (e) (n=4 animals per construct; one-way ANOVA with Tukey’s post hoc test; mean ± s.e.m.).
[0048] Figs 9(a-b) depict the binding curves of mCherry-StcEE447Dvariants on HeLa cells, (a) Binding curves of mCherry-StcEE447D, mCherry-StcEE447DΔINS, mCherry-StcEE447DΔC, mCherry-Cdom, and mCherry on HeLa cells. (b)Binding curves of mCherry-StcEE447Dand mCherry-C on HeLa cells with and without StcE treatment.
[0049] Figs. 10 (a-n) provide data demonstrating that mCherry-Cdom is internalized into brain endothelial cells in a caveolae- and mucin-dependent manner, (a) mCherry-Cdom internalization into hCMEC / D3 cells in a mucin-dependent manner. Scale bar=25 μm. (b) Quantification of mCherry MFI in (a) (n=4 wells per construct; one-way ANOVA with Dunnett’s post hoc test; mean ± s.e.m.). (c) mCherry-Cdom internalization into Neuro2a cells in a mucin-dependent manner. Scale bar=25 μm. (d) Quantification of mCherry MFI in (c) (n=4 wells per construct; one-way ANOVA with Sidak’s post hoc test; mean ± s.e.m.). (e) mCherry-Cdom internalization into the brain at 6 and 24 h quantified via ELISA (n=2 animals per group; one-way ANOVA with Tukey’s post hoc test; mean ± s.e.m ). (f) mCherry-Cdom colocalization with CAV1 and CLTC in bEnd.3 cells. Scale bar=25 μm. (g) Quantification of colocalization of mCherry-Cdom with caveolae and clathrin using Pearson correlation (n=3 wells per compartment; two-sided t-test; mean ± s.e.m.). (h) Quantification of mCherry-Cdom binding and internalization in bEnd.3 cells in the presence of different endocytosis inhibitors (n=3 wells per group; one-way ANOVA with Dunnett’s post hoc test; mean ± s.e.m.). (i) mCherry-Cdom internalization in wild-type (WT) and CAV1-KO cells. Scale bar=25 μm. (j) Quantification of mCherry MFI in (i) (n=3 wells per construct; one-way ANOVA with Dunnett’s post hoc test; mean ± s.e.m.). (k) mCherry-Cdom internalization in WT and CD34-KO cells. Scale bar=25 μm. (1) Quantification of mCherry MFI in (k) (n=3 wells per construct; two-sided t-test; mean ± s.e.m.). (m) Cherry-Cdom internalization in WT and PODXL-KO cells. Scale bar=25 μm. (n) Quantification of mCherry MFI in (m) (n=2 wells per construct; one-way ANOVA with Dunnett’s post hoc test; mean ± s.e.m.).
[0050] Fig. 11 (a-g) show characterization of mCherry-SMS variants, a) Structures of mCherry-SMS variants, as predicted by AlphaFold, b) Binding and internalization of mCherry-SMS1, mCherry-SMS1ΔINS, mCherry-SMS1ΔC, mCherry-SMS2, and mCherry in human primary brain endothelial cells after 30-min incubation at 37°C. Cell boundaries for mCherry-STDU2-44870.601SMS 1 AC and mCherry are marked in white dotted line. Scale bar=25 μm. c) Quantification of (b) (n=2-3 wells per construct; one-way ANOVA with Dunnett’s post hoc test; mean ± s.e.m.). d) Binding curves of mCherry-SMS1 and mCherry-SMS2 on HeLa cells with and without StcE treatment, e) mCherry-SMS2 colocalization with CAV1 and CLTC in bEnd.3 cells with colocalization threshold mask in grayscale. Scale bar=25 μm. f) Colocalization analysis using Pearson correlation between mCherry-SMS2 and CAV1 or CLTC in bEnd.3 cells (n=3 wells per construct; two-sided t-test; mean ± s.e.m.). g) mCherry-SMS2 internalization in wild-type (WT) and two CAV1-KO cell lines. Scale bar=25 μm. h) Quantification of mCherry MFI in (g) (n=3 wells per construct; one-way ANOVA with Dunnett’s post hoc test; mean ± s.e.m.).
[0051] Fig. 12 shows validation of vascular depletion, a) CD31 measurement in vascular cell, non-cellular, and parenchymal cell fractions by ELISA after vascular depletion (n=3 animals; oneway ANOVA with Tukey’s post hoc test; mean ± s.e.m.).DETAILED DESCRIPTION OF THE INVENTION
[0052] According to various embodiments, the present disclosure provides a novel class of engineered shuttle proteins that target specific glycoprotein motifs to internalize into brain endothelial cells and demonstrate effective brain delivery of different therapeutic cargo modalities. The presently disclosed engineered shuttle proteins were identified through interrogation of glycocalyx-binding proteins as a possible class of underexplored molecules for use as BBB transport vehicles for therapeutic delivery. The cerebrovascular glycocalyx is a carbohydrate-rich meshwork of proteoglycans, glycoproteins, and glycolipids that lines the vascular lumen. Despite its critical location at the blood-brain interface, this structure has been underutilized in the delivery of therapeutics in central nervous system (CNS) diseases (Fig. la). Presented herein is a new approach for CNS delivery and a distinct glycan-dependent pathway of internalization in brain endothelial cells, introducing new avenues for CNS disease treatments.Definitions
[0053] To facilitate an understanding of the present technology, a number of terms and phrases are defined below. Additional definitions are set forth throughout the detailed description.STDU2-44870.601
[0054] ‘ ‘About” and “approximately” are used to provide flexibility to a numerical range endpoint by providing that a given value may be “slightly above” or “slightly below” the endpoint without affecting the desired result, for example, + / - 5%.
[0055] The phrase “in one embodiment” or “in some embodiments” as used herein does not necessarily refer to the same embodiment, though it may. Furthermore, the phrase “in another embodiment” as used herein does not necessarily refer to a different embodiment, although it may. Thus, as described below, various embodiments of the invention may be readily combined, without departing from the scope or spirit of the invention.
[0056] The terms “comprise(s),” “include(s),” “having,” “has,” “can,” “contain(s),” and variants thereof, as used herein, are intended to be open-ended transitional phrases, terms, or words that do not preclude the possibility of additional acts or structures. The singular forms “a,” “and” and “the” include plural references unless the context clearly dictates otherwise. The present disclosure also contemplates other embodiments “comprising,” “consisting of’ and “consisting essentially of,” the embodiments or elements presented herein, whether explicitly set forth or not.
[0057] For the recitation of numeric ranges herein, each intervening number there between with the same degree of precision is explicitly contemplated. For example, for the range of 6-9, the numbers 7 and 8 are contemplated in addition to 6 and 9, and for the range 6.0-7.0, the number 6.0, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9, and 7.0 are explicitly contemplated.
[0058] “Subject” and “patient” as used herein interchangeably refers to any vertebrate, including, but not limited to, an animal (e.g., a bear, cow, cattle, pig, camel, llama, horse, goat, rabbit, sheep, hamster, guinea pig, cat, tiger, lion, cheetah, jaguar, bobcat, mountain lion, dog, wolf, coyote, rat. mouse, and a non-human primate (for example, a monkey, such as a cynomolgus or rhesus monkey, chimpanzee, etc.) and a human. In some embodiments, the subject is a human.
[0059] As defined herein, “neurological diseases” can be categorized according to the primary location affected, the primary type of dysfunction involved, or the primary type of cause. The broadest division is between central nervous system (CNS) disorders and peripheral nervous system (PNS) disorders. The Merck Manual lists brain, spinal cord and nerve disorders in the following overlapping categories, all of which are contemplated by the invention: brain damage according to cerebral lobe, i.e., Frontal lobe damage, Parietal lobe damage, Temporal lobe damage, and Occipital lobe damage; brain dysfunction according to type: Aphasia (language). Dysarthria (speech), Apraxia (patterns or sequences of movements), Agnosia (identifying things / people), andSTDU2-44870.601Amnesia (memory); spinal cord disorders; peripheral neuropathy & other peripheral nervous system disorders; cranial nerve disorders such as Trigeminal neuralgia; autonomic nervous system disorders, such as dysautonomia and Multiple System Atrophy; seizure disorders, such as epilepsy; movement disorders of the central & peripheral nervous system, such as Parkinson's disease, essential tremor, amyotrophic lateral sclerosis (ALS), Tourette's Syndrome, multiple sclerosis & various types of peripheral neuropathy; sleep disorders, such as narcolepsy; migraines and other types of headache, such as cluster headache and tension headache; lower back and neck pain; central Neuropathy (see Neuropathic pain); and neuropsychiatric illnesses (diseases and / or disorders with psychiatric features associated with known nervous system injury, underdevelopment, biochemical, anatomical, or electrical malfunction, and / or disease pathology e.g.. Attention deficit hyperactivity disorder, Autism, Tourette's Syndrome & some cases of Obsessive compulsive disorder as well as the neurobehavioral associated symptoms of degeneratives of the nervous system such as Parkinson's disease, Essential tremor, Huntington's disease. Alzheimer's disease, Multiple sclerosis & organic psychosis).
[0060] As used herein, the terms “treatment,” “treating,” and the like refer to obtaining a desired pharmacologic and / or physiologic effect. Preferably, the effect is therapeutic, i.e., the effect partially or completely alleviates or cures an injury, disease, and / or an adverse symptom attributable to the injury or disease. Similarly, a “therapeutic agent,” is any substance, molecule, or compound that is capable of alleviating or curing an injury, disease, and / or adverse symptom when administered to a subject in need thereof. To this end, the methods described herein desirably comprise administering a “therapeutically effective amount” of a therapeutic agent.
[0061] As used herein, “therapeutically effective amount” means the amount of a compound that, when administered to a patient for treating a disease, is sufficient to effect such treatment for the disease, e.g., the amount of such a substance that produces some desired local or systemic effect at a reasonable benefit / risk ratio applicable to any treatment, e.g.. is sufficient to ameliorate at least one sign or symptom of the disease, e.g., to prevent progression of the disease or condition, e.g., prevent tumor growth, decrease tumor size, induce tumor cell apoptosis, reduce tumor angiogenesis, prevent metastasis. When administered for preventing a disease, the amount is sufficient to avoid or delay onset of the disease. The “therapeutically effective amount” will vary depending on the compound, its therapeutic index, solubility, the disease and its severity and the age, weight, etc., of the patient to be treated, and the like. Administration of aSTDU2-44870.601therapeutically effective amount of a compound may require the administration of more than one dose of the compound. The therapeutically effective amount may vary according to factors such as the injury severity, age, sex, and weight of the individual, and the ability of therapeutic agent to elicit a desired response in the individual.
[0062] The term “antibody” as used herein refers to immunoglobulin molecules and immunologically active portions of immunoglobulin (Ig) molecules, i.e., molecules that contain an antigen-binding site that specifically binds (immunoreacts with) an antigen, comprising at least one. and preferably two, heavy (H) chain variable regions (abbreviated herein as VH), and at least one and preferably two light (L) chain variable regions (abbreviated herein as VL). Such antibodies include, but are not limited to, polyclonal, monoclonal, chimeric, single chain, Fab, Fab' and F(ab')2 fragments, and a Fab expression library. The VH and VL regions can be further subdivided into regions of hypervariability, termed “complementarity determining regions” (“CDR”), interspersed with regions that are more conserved, termed “framework regions” (FR). The extent of the framework region and CDR's has been precisely defined (see, Kabat, E. A., et al. (1991) Sequences of Proteins of Immunological Interest, Fifth Edition, U. S. Department of Health and Human Services, NIH Publication No. 91-3242, and Chothia, C. et al. (1987) J. Mol. Biol.196:901-917, which are incorporated herein by reference). Each VH and VL is composed of three CDR's and four FRs, arranged from amino-terminus to carboxy-terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4. In general, antibody molecules obtained from humans relates to any of the classes IgG, IgM, IgA, IgE and IgD, which differ from one another by the nature of the heavy chain present in the molecule. Certain classes have subclasses as well, such as IgGL IgG2, and others. Furthermore, in humans, the light chain may be a kappa chain or a lambda chain. Reference herein to antibodies includes a reference to all such classes, subclasses and types of human antibody species. Therapeutically useful antibodies further include “humanized” monoclonal antibodies, fully human antibodies, bispecific antibodies, and heteroconjugate antibodies.
[0063] For the purposes of the present disclosure, the term “modified” refers to a nucleotide sequence, amino acid sequence, protein, enzyme, gene or object or a product therefrom which has been intentionally modified in a laboratory or other environment and is thus, non-naturally-occurring.STDU2-44870.601
[0064] According to various embodiments, the present disclosure relates to methods of administering a therapeutic agent to the brain or central nervous system of a subject, for example to treat, ameliorate, or identify any number of conditions or diseases including, but not limited to, brain cancer or a neurological disease. The therapeutic agent may be for example any agent suitable for administration to the brain or central nervous system including a chemotherapeutic agent or a neurotherapeutic agent. Chemotherapeutic agents include any agents known to be therapeutic against cancers including brain cancers and cancers that have metastasized to the brain. Neurotherapeutic agents include, for example, PDGF, VEGF, dopamine and any agent known to be therapeutic to neurological diseases such as Alzheimer's disease, Parkinson’s disease, stroke, and the like.
[0065] According to some embodiments, the present disclosure provides a distinct glycan-targeted approach for brain delivery that leverages the brain endothelial glycocalyx as a novel entry pathway across the BBB. The disclosure identifies mucin-domain glycoproteins, which are abundantly expressed on the luminal surface of the BBB, as an underexplored yet promising class of targets for CNS drug delivery. While RMT systems such as those using transferrin or insulin receptors have been extensively studied for BBB transcytosis, they may be limited by receptor saturation, off-target effects, and suboptimal brain parenchymal distribution. The present disclosure demonstrates that mucin-binding protein StcEE447D(SMS1) and its engineered derivatives represent an alternative and mechanistically distinct class of brain shuttles. StcEE447Dexhibits robust, mucin-dependent internalization into mouse and human brain endothelial cells via a caveolae-mediated pathway, diverging from the clathrin-dependent uptake of classical RMT systems. In vivo. StcEE447Deffectively traffics beyond the vasculature into key brain cell types, including neurons, astrocytes, and microglia, highlighting its use for widespread parenchymal delivery.
[0066] According to various embodiments, the present disclosure presents the C-terminal domain of StcEE447D(SMS2) as a minimal functional unit responsible for mucin recognition and cellular uptake and demonstrated its modularity by fusing the C domain to a variety of therapeutic payloads for brain delivery. Fusion to an anti-BACE1 antibody facilitated efficient brain endothelial cell uptake in both monovalent and bivalent formats, which both outperformed a clinical anti-TfR comparator in internalization efficiency. (See Examples and Experimental, below.) Notably, the bivalent C domain conjugate effectively enhanced antibody uptake in vivo, achieving broadSTDU2-44870.601distribution across brain regions. Similarly, the C domain also facilitated successful delivery of hPGRN, a lysosomal protein implicated in FTD, into brain endothelial cells and across the BBB in vivo. These data support the versatility of mucin-binding shuttles as a delivery platform for diverse CNS -targeted therapeutics.
[0067] The full-length mucin-binding shuttle protein SMS 1 comprises the amino acid sequence set forth in SEQ ID NO:1. SMS1 is an enzymatically inactive mucinase derived from Escherichia coli secreted protease C (StcE), bearing an E447D substitution that abolishes catalytic activity while preserving mucin-binding capacity. SMS1 comprises three globular domains: an immunoglobulin-like (IG) domain, an insertion (INS) region, a metalloprotease (M) domain, additional disordered (D) regions, and a C-terminal domain (C domain). The full-length SMS 1 protein has a molecular weight of approximately 98 kDa.
[0068] The C-terminal domain of SMS1, designated herein as SMS2, comprises the amino acid sequence set forth in SEQ ID NO:2. SMS2 has a molecular weight of approximately 10-11 kDa and represents a minimal functional unit of SMS 1 that is useful and sufficient for mucin-dependent binding, caveolae-mediated internalization into brain endothelial cells, and transport of associated cargo across the blood-brain barrier. As demonstrated herein, SMS2 retains the brain delivery efficiency of full-length SMS1 while exhibiting reduced peripheral tissue uptake, favorable pharmacokinetics, and improved compatibility with larger or structurally constrained therapeutic payloads.
[0069] According to various embodiments, the present disclosure provides mucin-binding shuttle proteins comprising an amino acid sequence having at least about 70%, at least about 75%, at least about 80%. at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to SEQ ID NO: 1. In some embodiments, the mucin-binding shuttle protein comprises an amino acid sequence having at least about 70%. at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%. at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to SEQ ID NO:2. In certain preferred embodiments, the mucin-binding shuttle protein comprises an amino acid sequence having at least about 80% sequence identity to SEQ ID NO:2. In certain furtherSTDU2-44870.601preferred embodiments, the mucin-binding shuttle protein comprises an amino acid sequence having at least about 90% sequence identity to SEQ ID NO:2.
[0070] As used herein, "percent sequence identity" between two amino acid sequences is determined by aligning the sequences for optimal comparison purposes, including the introduction of gaps as necessary, and determining the number of positions at which identical amino acid residues occur in both sequences relative to the total number of positions in the aligned sequences. Sequence identity may be determined using standard algorithms known in the art, including but not limited to the BLAST algorithm (Altschul et al., J. Mol. Biol., 215:403-410, 1990), the Needleman-Wunsch algorithm (Needleman and Wunsch, J. Mol. Biol., 48:443-453, 1970), or the Smith- Waterman algorithm (Smith and Waterman, J. Mol. Biol., 147:195-197, 1981). Unless otherwise specified, default parameters of the respective algorithms are employed. In each of the foregoing embodiments, the variant retains the functional property of mucin-dependent binding and internalization into brain endothelial cells.
[0071] In various embodiments, the mucin-binding shuttle proteins of the present disclosure encompass variants of SEQ ID NO:1 or SEQ ID NO:2 that contain one or more amino acid substitutions relative to the reference sequence, provided that such variants retain the ability to bind mucin-domain glycoproteins and to mediate internalization into brain endothelial cells via a caveolae-dependent pathway.
[0072] In some embodiments, the variant comprises one or more conservative amino acid substitutions. As used herein, a "conservative amino acid substitution" refers to a substitution in which an amino acid residue is replaced by another amino acid residue having a side chain with similar physicochemical properties. Families of amino acid residues having similar side chains are well known in the art and include: basic side chains (e.g., lysine, arginine, and histidine); acidic side chains (e.g., aspartic acid and glutamic acid); uncharged polar side chains (e.g., asparagine, glutamine, serine, threonine, and tyrosine); nonpolar side chains (e.g., glycine, alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, and tryptophan); beta-branched side chains (e.g., threonine, valine, and isoleucine); and aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, and histidine). In certain embodiments, the variant comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more conservative amino acid substitutions relative to SEQ ID NO:1 or SEQ ID NO:2.STDU2-44870.601
[0073] In some embodiments, the variant comprises one or more non-conservative amino acid substitutions. As used herein, a "non-conservative amino acid substitution" refers to a substitution in which an amino acid residue is replaced by an amino acid residue having a side chain with substantially different physicochemical properties from the replaced residue, for example, substitution of a charged residue for a nonpolar residue, a large hydrophobic residue for a small polar residue, or the like. In certain embodiments, such non-conservative substitutions are made at positions outside of the mucin-binding interface or other functionally critical regions of the shuttle protein, such that the variant retains mucin-binding and internalization activity, In various embodiments, the variant comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more non-conservative amino acid substitutions relative to SEQ ID NO:1 or SEQ ID NO:2.
[0074] In further embodiments, the variant comprises a combination of conservative and non-conservative amino acid substitutions. In some such embodiments, the variant contains no more than about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, or 30 total amino acid substitutions (whether conservative, non-conservative, or a combination thereof) relative to the reference sequence.
[0075] In certain embodiments, the variant further comprises one or more amino acid insertions, deletions, or combinations thereof, in addition to or in the alternative to amino acid substitutions, relative to SEQ ID NO:1 or SEQ ID NO:2, provided that the variant retains mucin-binding and brain endothelial cell internalization activity.
[0076] The present disclosure further provides truncated variants of SMS1 that comprise the C domain (SMS2) or a functional portion thereof and that retain the ability to bind mucin-domain glycoproteins and mediate transport across the blood-brain barrier. The inventors have demonstrated that the C domain is useful and sufficient for mucin-dependent cellular uptake and brain delivery, and that the IG domain, INS region, and metalloprotease (M) domain are dispensable for these functions. Accordingly, truncated constructs lacking one or more of these non-essential domains while retaining the C domain are encompassed by the present disclosure.
[0077] In some embodiments, the truncated mucin-binding shuttle protein comprises the C domain of SMS1 and lacks the INS region relative to SEQ ID NO:1. As demonstrated herein, a deletion construct lacking the INS region (designated SMS1AINS) retains robust cellular uptake and brain delivery activity comparable to full-length SMS1.STDU2-44870.601
[0078] In some embodiments, the truncated mucin-binding shuttle protein comprises the C domain of SMS1 and lacks one or more of the IG domain, the INS region, and the metalloprotease (M) domain relative to SEQ ID NO:1.
[0079] In some embodiments, the truncated mucin-binding shuttle protein comprises the C domain of SMS1 and one or more additional domains or regions selected from the group consisting of the IG domain, the INS region, the metalloprotease (M) domain, and the disordered (D) regions of SEQ ID NO: 1.
[0080] In some embodiments, the truncated mucin-binding shuttle protein consists essentially of the C domain and one or more disordered (D) regions of SMS1.
[0081] In some embodiments, the truncated mucin-binding shuttle protein has a molecular weight of between about 10 kDa and about 98 kDa, or between about 10 kDa and about 80 kDa. or between about 10 kDa and about 60 kDa, or between about 10 kDa and about 40 kDa, or between about 10 kDa and about 20 kDa.
[0082] In each of the foregoing truncation embodiments, the truncated mucin-binding shuttle protein retains the functional properties of mucin-dependent binding and caveolae-mediated internalization into brain endothelial cells. The truncated variants may further comprise amino acid substitutions (conservative, non-conservative, or both) and / or sequence identity variations as described hereinabove with respect to SEQ ID NO:1 and SEQ ID NO:2.
[0083] The present disclosure further provides functional fragments of the C domain (SEQ ID NO:2) that retain the ability to bind mucin-domain glycoproteins and mediate internalization into brain endothelial cells via a caveolae-dependent pathway. As used herein, a "functional fragment" of the C domain refers to a contiguous amino acid sequence derived from SEQ ID NO:2 that is shorter than full-length SEQ ID NO:2 but that retains mucin-binding activity and the capacity to mediate cellular uptake and / or transport across the blood-brain barrier.
[0084] In some embodiments, the functional fragment of the C domain comprises at least about 50, at least about 55, at least about 60, at least about 65, at least about 70, at least about 75, at least about 80, at least about 85, at least about 90, or at least about 95 contiguous amino acid residues of SEQ ID NO:2.
[0085] In some embodiments, the functional fragment of the C domain comprises at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 85%, at least about 90%, or at least about 95% of the total amino acid residues of SEQ ID NO:2.STDU2-44870.601
[0086] In some embodiments, the functional fragment of the C domain comprises the mucinbinding interface residues of SEQ ID NO:2. Without wishing to be bound by theory, it is believed that residues critical for mucin recognition and binding are localized within specific surface-exposed regions of the C domain, and that functional fragments retaining these residues and sufficient surrounding structural context to maintain proper folding and presentation of the mucinbinding surface will retain the internalization properties demonstrated herein.
[0087] In some embodiments, the functional fragment of the C domain comprises N-terminal and / or C-terminal truncations of SEQ ID NO:2 of up to about 5, up to about 10, up to about 15, up to about 20, up to about 25, or up to about 30 amino acid residues from the N-terminus, the C-terminus, or both the N-terminus and C-terminus of SEQ ID NO:2.
[0088] In certain embodiments, the functional fragment of the C domain has a molecular weight of at least about 5 kDa, at least about 6 kDa, at least about 7 kDa, at least about 8 kDa, at least about 9 kDa, or at least about 10 kDa.
[0089] In each of the foregoing embodiments, the functional fragment may further comprise one or more amino acid substitutions (conservative, non-conservative, or both) as described hereinabove, provided that the fragment retains mucin-binding and internalization activity. In certain embodiments, the functional fragment has at least about 70%, at least about 80%, at least about 90%, at least about 95%, or at least about 99% sequence identity to a corresponding contiguous portion of SEQ ID NO:2.
[0090] As used herein, a variant, truncation, or functional fragment of SMS1 or SMS2 is considered to "retain" mucin-binding and internalization activity if, when assessed in an in vitro cellular internalization assay using brain endothelial cells (e.g., bEnd.3 cells or human primary brain microvascular endothelial cells), the variant, truncation, or functional fragment: (a) exhibits mucin-dependent binding to the cell surface, as evidenced by a reduction in binding upon enzymatic removal of cell surface mucins (e.g., by treatment with StcE mucinase); and (b) demonstrates internalization into the cells at a level that is at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, or about 100% of the internalization level observed with the corresponding reference sequence (SEQ ID NO:1 or SEQ ID NO:2, as applicable) when assessed under comparable conditions.STDU2-44870.601
[0091] In further embodiments, a variant, truncation, or functional fragment is considered to retain brain delivery activity if, when administered intravenously to a subject (e.g., a mouse) as a fusion to a detectable cargo protein (e.g., mCherry), the variant, truncation, or functional fragment mediates detectable cargo accumulation in the brain parenchyma at a level above that observed for the cargo protein alone.
[0092] The present disclosure further encompasses mucin-binding shuttle proteins derived from orthologs or homologs of StcE from bacterial species other than E. coli, provided that such orthologs or homologs, or domains thereof, retain mucin-binding and brain endothelial cell internalization activity. In some embodiments, the mucin-binding shuttle protein comprises a C-terminal domain from a StcE ortholog or homolog having at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, or at least about 95% sequence identity to SEQ ID NO:2. In various embodiments, such orthologs or homologs are identified by sequence alignment, structural homology modeling, or functional screening for mucin-binding and internalization activity as described herein.
[0093] In certain embodiments, the mucin-binding shuttle proteins disclosed herein (including SMS1, SMS2, variants, truncations, and functional fragments thereof) may be further engineered to incorporate modifications that enhance one or more properties desirable for therapeutic applications. Such modifications include, but are not limited to: introduction of non-natural amino acids; PEGylation or conjugation to other half-life extending moieties; introduction of proteaseresistant substitutions; glycoengineering to alter glycosylation patterns; fusion to albumin, an Fc domain, or other serum half-life extending domains; introduction of site- specific conjugation handles (e.g., engineered cysteine residues, unnatural amino acids, or sortase recognition motifs) for attachment of therapeutic payloads, detectable labels, or other functional moieties; and circularly permuted variants in which the N- and C-termini of the shuttle are rearranged while preserving the overall fold and mucin-binding activity. In each such embodiment, the engineered mucin-binding shuttle protein retains the ability to bind mucin-domain glycoproteins and to mediate internalization into brain endothelial cells.
[0094] According to various embodiments, the mucin-binding shuttle proteins disclosed herein (including SMS1, SMS2, variants, truncations, and functional fragments thereof) are connected to one or more cargo molecules via a linker. As used herein, a "linker" refers to a chemical moiety, amino acid sequence, or other molecular entity that covalently connects the mucin-binding shuttleSTDU2-44870.601protein to one or more cargo molecules while maintaining the functional properties of both the shuttle and the cargo. The linker may connect the shuttle to the cargo at the N-terminus or C-terminus of the shuttle, at the N-terminus or C-terminus of the cargo, at an internal position of either the shuttle or cargo, or at any combination thereof. In embodiments where SMS2 is fused to a cargo protein, the orientation of the fusion may be selected to preserve critical functional domains of the cargo. For example, as demonstrated herein. SMS2 was fused to the N-terminus of human progranulin (hPGRN) to preserve the C-terminal lysosomal targeting motifs of hPGRN, while SMS2 was fused to the C-terminus of an anti-BACE1 antibody heavy chain to preserve the antigen-binding function of the antibody. The skilled artisan will appreciate that the choice of fusion orientation may be determined based on the structural and functional requirements of the particular cargo molecule.
[0095] In some embodiments, the linker is a peptide linker. Peptide linkers are particularly suitable for embodiments in which the shuttle and cargo are expressed as a genetic fusion, either from a single recombinant expression construct or through chemical peptide synthesis. In some embodiments, the peptide linker comprises from about 1 to about 100 amino acid residues, or from about 2 to about 80 amino acid residues, or from about 3 to about 60 amino acid residues, or from about 4 to about 50 amino acid residues, or from about 5 to about 40 amino acid residues, or from about 5 to about 30 amino acid residues, or from about 5 to about 20 amino acid residues, or from about 5 to about 15 amino acid residues.
[0096] In some embodiments, the peptide linker is a flexible linker. As used herein, a "flexible linker" refers to a peptide linker that adopts a predominantly disordered or extended conformation in solution, thereby providing spatial separation between the shuttle and cargo domains and permitting independent folding and function of each domain. In certain embodiments, the flexible linker is rich in small, non-bulky amino acid residues such as glycine, serine, alanine, and threonine.
[0097] In some embodiments, the peptide linker is a rigid linker. As used herein, a "rigid linker" refers to a peptide linker that adopts a predominantly alpha-helical or other ordered secondary structure, thereby providing a more defined spatial separation between the shuttle and cargo domains and minimizing interdomain interactions.STDU2-44870.601
[0098] In some embodiments, the peptide linker is a semi-rigid or semi-flexible linker that comprises a combination of flexible and rigid elements. In certain embodiments, such a linker comprises one or more proline residues interspersed within a glycine-serine-rich sequence.
[0099] In some embodiments, the peptide linker comprises one or more naturally occurring interdomain linker sequences derived from multi-domain proteins. In some embodiments, the peptide linker comprises an immunoglobulin hinge region sequence or a portion thereof. In certain embodiments, the peptide linker is derived from the hinge region of a human IgGl, IgG2, IgG3, or IgG4 antibody.
[0100] In some embodiments, the linker is a cleavable linker. As used herein, a "cleavable linker" refers to a linker that can be cleaved under specified conditions to release the cargo molecule from the shuttle protein. Cleavable linkers may be advantageous in embodiments where release of the cargo from the shuttle following transcytosis across the blood-brain barrier is desirable for optimal cargo activity, intracellular trafficking, or target engagement within the brain parenchyma.
[0101] In some embodiments, the cleavable linker is a protease-cleavable linker comprising a peptide sequence that is recognized and cleaved by an endogenous protease. In certain embodiments, the protease-cleavable linker comprises a recognition sequence for a protease selected from the group consisting of: matrix metalloproteinases (MMPs), cathepsins (e.g., cathepsin B, cathepsin D, cathepsin L), furin, thrombin, factor Xa, enterokinase, TEV protease, and caspases.
[0102] In some embodiments, the cleavable linker is a pH-sensitive linker that is cleaved or hydrolyzed under acidic conditions encountered within endosomal or lysosomal compartments (e.g., pH about 4.5 to about 6.5). In certain embodiments, the pH-sensitive linker comprises a hydrazone bond, an acetal bond, a ketal bond, a cis-aconitic acid derivative, an orthoester bond, or a Schiff base.
[0103] In some embodiments, the cleavable linker is a disulfide-containing linker that is cleaved under reducing conditions, such as those encountered in the intracellular environment. In certain embodiments, the disulfide-containing linker comprises a disulfide bond flanked by one or more methyl groups or other steric elements to modulate the rate of reduction and cleavage.
[0104] In some embodiments, the cleavable linker is a self-immolative linker that undergoes spontaneous fragmentation following an initial cleavage or triggering event, thereby releasing the cargo in an unmodified form. In certain embodiments, the self-immolative linker comprises a para-STDU2-44870.601aminobenzyloxycarbonyl (PABC) group, a cyclization-based self-elimination spacer, or another self-immolative moiety known in the art.
[0105] In some embodiments, the shuttle and cargo are connected through a chemical linker rather than or in addition to a peptide linker. Chemical linkers may be advantageous in embodiments where the cargo molecule is not a protein or peptide, where genetic fusion is not feasible or desirable, or where site-specific conjugation with controlled stoichiometry is desired.
[0106] In some embodiments, the shuttle protein is engineered to comprise one or more sitespecific conjugation handles to facilitate controlled attachment of cargo molecules. In certain embodiments, the conjugation handle comprises an engineered cysteine residue at a defined position in the shuttle protein. I
[0107] In some embodiments, the shuttle and cargo are connected through a non-covalent association.
[0108] In some embodiments, the linker comprises a polyethylene glycol (PEG) moiety. PEG linkers may be advantageous in embodiments where it is desirable to increase the hydrodynamic radius of the shuttle-cargo conjugate to extend plasma half-life, to reduce immunogenicity, or to provide a hydrophilic spacer between the shuttle and cargo domains.
[0109] In some embodiments, a single cargo molecule (e.g., an antibody) is conjugated to two or more mucin-binding shuttle domains (e.g., two SMS2 domains) via separate linkers, thereby generating a multivalent shuttle-cargo conjugate. As demonstrated herein, bivalent attachment of SMS2 to an anti-BACE1 antibody enhanced internalization into brain endothelial cells relative to monovalent attachment.
[0110] In various embodiments, the linker is selected based on one or more of the following considerations: the desired spatial separation between the shuttle and cargo; the need to preserve independent folding and function of both the shuttle and the cargo; the compatibility of the linker with the expression system (e.g.. bacterial or mammalian); the stability of the linker under physiological conditions, including resistance to serum proteases; the need for controlled release of the cargo from the shuttle following brain delivery; the manufacturing feasibility and scalability of the conjugation method; and the immunogenicity profile of the linker.
[0111] In some embodiments, the linker has a length of from about 0.5 nm to about 20 nm, or from about 1 nm to about 15 nm, or from about 2 nm to about 10 nm, as measured in an extended conformation or as estimated from the number of amino acid residues or PEG units in the linker.STDU2-44870.601
[0112] In each of the foregoing linker embodiments, the shuttle-linker-cargo conjugate retains the ability of the mucin-binding shuttle to bind mucin-domain glycoproteins and to mediate internalization into brain endothelial cells via a caveolae-dependent pathway. In certain embodiments, the shuttle-linker-cargo conjugate further retains the biological activity of the cargo molecule (e.g., antigen-binding activity for an antibody cargo, enzymatic activity for an enzyme cargo, or lysosomal targeting and function for a lysosomal protein cargo).
[0113] Therapeutic agents can include any neurologically active agents acting at synaptic and neuroeffector junction sites. The neurologically active agent useful in the present invention may be one that acts at the synaptic and neuroeffector junctional sites including, but not limited to, a cholinergic agonist, a anticholinesterase agent, catecholamine and other sympathomimetic drugs, an adrenergic receptor antagonist, an antimuscarinic drug, and an agent that acts at the neuromuscular junction and autonomic ganglia.
[0114] Examples of suitable cholinergic agonists include, but are not limited to, choline chloride, acetylcholine chloride, methacholine chloride, carbachol chloride, bethanechol chloride, pilocarpine, muscarine, arecoline and the like.
[0115] Suitable anticholinesterase agents are exemplified by the group consisting of carbaril, physostigmine, neostigmine, edrophonium, pyridostigmine, demecarium, ambenonium, tetrahydroacridine and the like.
[0116] Suitable catecholamines and sympathomimetic drugs include the subclasses of endogenous catecholamines, beta-adrenergic agonists, alpha- adrenergic agonists and other miscellaneous adrenergic agonists.
[0117] Within the subclass of endogenous catecholamines, suitable examples include epinephrine, norepinephrine, dopamine and the like. Suitable examples within the subclass of beta-adrenergic agonists include, but are not limited to, isoproterenol, dobutamine, metaproterenol, terbutaline, albuterol, isoetharine. pirbuterol. bitolterol. ritodrine and the like. The subclass of a-adrenergic agonists can be exemplified by methoxamine, phenylephrine, mephentermine, metaraminol, clonidine, guanfacine, guanabenz, methyldopa and the like. Other miscellaneous adrenergic agents include, but are not limited to, amphetamine, methamphetamine, methylphenidate, pemoline, ephedrine and ethylnorepinephrine and the like.
[0118] Adrenergic receptor antagonists include the subclasses of a-adrenergic receptor antagonists and P-adrenergic receptor antagonists. Suitable examples of neurologically active agents that canSTDU2-44870.601be classified as a-adrenergic receptor antagonists include, but are not limited to, phenoxybenzamine and related haloalkylamines, phentolamine, tolazoline, prazosin and related drugs, ergot alkaloids and the like. Either selective or nonselective P-adrenergic receptor antagonists are suitable for use in the present invention, as are other miscellaneous P-adrenergic receptor antagonists.
[0119] Antimuscarinic drugs are exemplified by the group consisting of atropine, scopolamine, homatropine, belladonna, methscopolamine, methantheline, propantheline, ipratropium, cyclopentolate, tropicamide, pirenzepine and the like.
[0120] In addition, therapeutic agents that act at the neuromuscular junction and autonomic ganglia are contemplated. Suitable examples of such neurologically active agents that can be classified as agents that act at the neuromuscular junction and autonomic ganglia include, but are not limited to tubocurarine, alcuronium, P-Erythroidine, pancuronium, gallamine, atracurium, decamethonium, succinylcholine, nicotine, labeline, tetramethylammonium, l,l-dimethyl-4-phenylpiperazinium, hexamethonium, pentolinium, trimethaphan and mecamylamine, and the like.
[0121] Therapeutic agents that act on the central nervous system and the peripheral nervous system are also contemplated. Such neurologically active agents can include nonpeptide neurotransmitters, peptide neurotransmitters and neurohormones, proteins associated with membranes of synaptic vessels, neuromodulators, neuromediators, sedative-hypnotics, antiepileptic therapeutic agents, therapeutic agents effective in the treatment of Parkinsonism and other movement disorders, opioid analgesics and antagonists and antipsychotic compounds.
[0122] Nonpeptide neurotransmitters include the subclasses of neutral amino acids — such as glycine and gamma-aminobutyric acid and acidic amino acids — such as glutamate, aspartate, and NMD A receptor antagonist-MK801 (Dizocilpine Maleate). Other suitable nonpeptide neurotransmitters are exemplified by acetylcholine and the subclass of monoamines — such as dopamine, norepinephrine, 5-hydroxytryptamine, histamine, and epinephrine.
[0123] Neurotransmitters and neurohormones that are neuroactive peptides include the subclasses of hypothalamic-releasing hormones, neurohypophyseal hormones, pituitary peptides, invertebrate peptides, gastrointestinal peptides, atrial naturetic peptide, and other neuroactive peptides.STDU2-44870.601
[0124] The subclass of hypothalamic releasing hormones includes as suitable examples, thyrotropin-releasing hormones, gonadotropin-releasing hormone, somatostatins, corticotropinreleasing hormone and growth hormone- releasing hormone.
[0125] The subclass of neurohypophyseal hormones is exemplified by agents such as vasopressin, oxytocin, and neurophysins. Likewise the subclass of pituitary peptides is exemplified by the group consisting of adrenocorticotropic hormone, beta-endorphin, alpha-melanocyte-stimulating hormone, prolactin, luteinizing hormone, growth hormone, and thyrotropin.
[0126] Suitable invertebrate peptides are exemplified by the group comprising FMRF amide, hydra head activator, proctolin, small cardiac peptides, myomodulins, buccolins, egg-laying hormone and bag cell peptides. The subclass of gastrointestinal peptides includes such therapeutic agents as vasoactive intestinal peptide, cholecystokinin, gastrin, neurotensin, methionineenkephalin, leucine-enkephalin, insulin and insulin-like growth factors I and II, glucagon, peptide histidine isoleucineamide, bombesin, motilin and secretins.
[0127] Suitable examples of other neuroactive peptides include angiotensin II, bradykinin, dynorphin, opiocortins, sleep peptide(s), calcitonin, CGRP (calcitonin gene-related peptide), neuropeptide Y, neuropeptide Yy, galanin, substance K (neurokinin), physalaemin, Kassinin, uperolein, eledoisin and atrial naturetic peptide.
[0128] Proteins associated with membranes of synaptic vesicles include the subclasses of calcium-binding proteins and other synaptic vesicle proteins. The subclass of calcium-binding proteins further includes the cytoskeleton-associated proteins — such as caldesmon, annexins, calelectrin (mammalian), calelectrin (torpedo), calpactin I, calpactin complex, calpactin II, endonexin I, endonexin II, protein II, synexin I; and enzyme modulators, such as p65. Other synaptic vesicle proteins include inhibitors of mobilization (such as synapsin Ia,b and synapsin IIa,b), possible fusion proteins such as synaptophysin, and proteins of unknown function such as p29, VAMP- 1,2 (synaptobrevin), VAT-1, rab 3 A, and rab 3B.
[0129] Neuromodulators can be exemplified by the group consisting of CO2 and ammonia, steroids and steroid hormones, adenosine and other purines, and prostaglandins.
[0130] Neuromediators can be exemplified by the group consisting of cyclic AMP, cyclic GMP, and cyclic nucleotide-dependent protein phosphorylation reactions.
[0131] Sedative-hypnotics can be exemplified by the group consisting of benzodiazepines and buspirone, barbiturates, and miscellaneous sedative-hypnotics.STDU2-44870.601
[0132] Suitable antiepileptic drugs can be exemplified by the groups consisting of, but not limited to, hydantoins such as phenytoin, mephenytoin, and ethotoin; anticonvulsant barbiturates such as phenobarbital and mephobarbital; deoxybarbiturates such as primidone; iminostilbenes such as carbamazepine; succinimides such as ethosuximide, methsuximide, and phensuximide; valproic acid; oxazolidinediones such as trimethadione and paramethadione; benzodiazepines and other antiepileptic agents such as phenacemide, acetazolamide, and progabide.
[0133] Neurologically active agents that are effective in the treatment of Parkinsonism and other movement disorders include, but are not limited to, dopamine, levodopa, carbidopa, amantadine, baclofen, diazepam, dantrolene, dopaminergic agonists such as apomorphine, ergolines such as bromocriptine, pergolide, and lisuride, and anticholinergic drugs such as benztropine mesylate, trihexyphenidyl hydrochloride, procyclidine hydrochloride, biperiden hydrochloride, ethopropazine hydrochloride, and diphenhydramine hydrochloride.
[0134] Suitable opioid analgesics and antagonists can be exemplified by the group consisting of, but not limited to, endogenous opioid peptides such as enkephalins, endorphins, and dynorphins; morphine and related opioids such as levorphanol and congeners; meperidine and congeners such as piperidine, phenylpiperidine, diphenoxylate, loperamide, and fentanyl; methadone and congeners such as methadone and propoxyphene; pentazocine; nalbuphine; butorphanol; buprenorphine; meptazinol; opioid antagonists such as naloxone hydrochloride; and centrally active antitussive agents such as dextromethorphan.
[0135] Neurologically active agents that can be used to treat depression, anxiety or psychosis are also contemplated. Suitable antipsychotic compounds include, but are not limited to, phenothiazines, thioxanthenes, dibenzodiazepines, butyrophenones, diphenylbutylpiperidines, indolones, and rauwolfia alkaloids. Mood alteration drugs that are suitable for use in the present invention include, but are not limited to, tricyclic antidepressants (which include tertiary amines and secondary amines), atypical antidepressants, and monoamine oxidase inhibitors. Examples of suitable drugs that are used in the treatment of anxiety include, but are not limited to, benzodiazepines.
[0136] A neurologically active therapeutic agent may be a neuroactive protein, such as human and chimeric mouse / human monoclonal antibodies, erythropoietin and G-CSF, orthoclone OKT3, interferon-gamma. interleukin- 1 receptors, t-PA (tissue-type plasminogen activator), recombinant streptokinase, superoxide dismutase, tissue factor pathway inhibitor (TFPI). Alternatively, theSTDU2-44870.601neurologically active agent may be a neuroactive nonprotein drug, such as neurotransmitter receptors and pharmacological targets in Alzheimer's disease; Design and Synthesis of BMY21502: A Potential Memory and Cognition Enhancing Agent; muscarinic agonists for the central nervous system; serotonic receptors, agents, and actions; thiazole-containing 5-hydroxytryptamine-3 receptor antagonists; acidic amino acids as probes of glutamate receptors and transporters; E-2-(carboxycyclopropyl)glycines; and N-Methyl-D-aspartic acid receptor antagonists.
[0137] The invention also contemplates administration of cancer therapies through the BBB. Nonlimiting examples of anti-cancer agents and drugs that can be used in combination with one or more compositions and methods of the invention for the treatment of cancer include, but are not limited to, one or more of: 20-epi-l,25 dihydroxyvitamin D3, 4-ipomeanol, 5-ethynyluracil, 9-dihydrotaxol, abiraterone, acivicin, aclarubicin, acodazole hydrochloride, acronine, acylfulvene, adecypenol, adozelesin, aldesleukin, all-tk antagonists, altretamine, ambamustine, ambomycin, ametantrone acetate, amidox, amifostine, aminoglutethimide, aminolevulinic acid, amrubicin, amsacrine, anagrelide, anastrozole, andrographolide, angiogenesis inhibitors, antagonist D, antagonist G, antarelix, anthramycin, anti-dorsalizing morphogenetic protein- 1, antiestrogen, antineoplaston, antisense oligonucleotides, aphidicolin glycinate, apoptosis gene modulators, apoptosis regulators, apurinic acid, ARA-CDP-DL-PTBA, arginine deaminase, asparaginase, asperlin, asulacrine, atamestane, atrimustine, axinastatin 1, axinastatin 2, axinastatin 3, azacitidine, azasetron, azatoxin, azatyrosine, azetepa, azotomycin, baccatin III derivatives, balanol, batimastat, benzochlorins, benzodepa, benzoylstaurosporine, beta lactam derivatives, beta-alethine, betaclamycin B, betulinic acid, BFGF inhibitor, bicalutamide, bisantrene, bisantrene hydrochloride, bisaziridinylspermine, bisnafide, bisnafide dimesylate, bistratene A, bizelesin, bleomycin, bleomycin sulfate, BRC / ABE antagonists, breflate, brequinar sodium, bropirimine, budotitane. busulfan, buthionine sulfoximine, cactinomycin, calcipotriol. calphostin C, calusterone, camptothecin derivatives, canarypox IE-2, capecitabine, caracemide, carbetimer, carboplatin, carboxamide-amino-triazole, carboxyamidotriazole, carest M3, carmustine, cam 700, cartilage derived inhibitor, carubicin hydrochloride, carzelesin, casein kinase inhibitors, castanospermine, cecropin B, cedefingol, cetrorelix, chlorambucil, chlorins, chloroquinoxaline sulfonamide, cicaprost, cirolemycin, cisplatin, cis-porphyrin, cladribine, clomifene analogs, clotrimazole, collismycin A, collismycin B, combretastatin A4, combretastatin analog, conagenin,STDU2-44870.601crambescidin 816, crisnatol, crisnatol mesylate, cryptophycin 8, cryptophycin A derivatives, curacin A, cyclopentanthraquinones, cyclophosphamide, cycloplatam, cypemycin, cytarabine, cytarabine ocfosfate, cytolytic factor, cytostatin, dacarbazine. dacliximab, dactinomycin, daunorubicin hydrochloride, decitabine, dehydrodidemnin B, deslorelin, dexifosfamide, dexormaplatin, dexrazoxane, dexverapamil, dezaguanine, dezaguanine mesylate, diaziquone, didemnin B, didox, diethylnorspermine, dihydro-5 -azacytidine, dioxamycin, diphenyl spiromustine, docetaxel, docosanol, dolasetron, doxifluridine, doxorubicin, doxorubicin hydrochloride, droloxifene, droloxifene citrate, dromostanolone propionate, dronabinol, duazomycin, duocarmycin SA, ebselen, ecomustine, edatrexate, edelfosine, edrecolomab, eflornithine, eflornithine hydrochloride, elemene, elsamitrucin, emitefur, enloplatin, enpromate, epipropidine. epirubicin, epirubicin hydrochloride, epristeride, erbulozole, erythrocyte gene therapy vector system, esorubicin hydrochloride, estramustine, estramustine analog, estramustine phosphate sodium, estrogen agonists, estrogen antagonists, etanidazole, etoposide, etoposide phosphate, etoprine, exemestane, fadrozole, fadrozole hydrochloride, fazarabine, fenretinide, filgrastim, finasteride, flavopiridol, flezelastine, floxuridine, fluasterone, fludarabine, fludarabine phosphate, fluorodaunorunicin hydrochloride, fluorouracil, flurocitabine, forfenimex, formestane, fosquidone, fostriecin, fostriecin sodium, fotemustine, gadolinium texaphyrin, gallium nitrate, galocitabine, ganirelix, gelatinase inhibitors, gemcitabine, gemcitabine hydrochloride, glutathione inhibitors, hepsulfam, heregulin, hexamethylene bisacetamide, hydroxyurea, hypericin, ibandronic acid, idarubicin, idarubicin hydrochloride, idoxifene, idramantone, ifosfamide, ilmofosine, ilomastat, imidazoacridones, imiquimod, immunostimulant peptides, insulin-like growth factor- 1 receptor inhibitor, interferon agonists, interferon alpha-2A, interferon alpha-2B, interferon alpha-Nl, interferon alpha-N3, interferon beta-IA, interferon gamma-IB, interferons, interleukins, iobenguane, iododoxorubicin, iproplatin. irinotecan, irinotecan hydrochloride, iroplact, irsogladine, isobengazole, isohomohalicondrin B, itasetron, jasplakinolide, kahalalide F, lamellarin-N triacetate, lanreotide, lanreotide acetate, leinamycin, lenograstim, lentinan sulfate, leptolstatin, letrozole, leukemia inhibiting factor, leukocyte alpha interferon, leuprolide acetate, leuprolide / estrogen / progesterone, leuprorelin, levamisole, liarozole, liarozole hydrochloride, linear polyamine analog, lipophilic disaccharide peptide, lipophilic platinum compounds, lissoclinamide 7, lobaplatin, lombricine, lometrexol, lometrexol sodium, lomustine, lonidamine, losoxantrone, losoxantrone hydrochloride, lovastatin, loxoribine, lurtotecan, lutetium texaphyrin,STDU2-44870.601lysofylline, lytic peptides, maitansine, mannostatin A, marimastat, masoprocol, maspin, matrilysin inhibitors, matrix metalloproteinase inhibitors, maytansine, mechlorethamine hydrochloride, megestrol acetate, melengestrol acetate, melphalan, menogaril, merbarone, mercaptopurine, meterelin, methioninase, methotrexate, methotrexate sodium, metoclopramide, metoprine, meturedepa, microalgal protein kinase C inhibitors, MIF inhibitor, mifepristone, miltefosine, mirimostim, mismatched double stranded RNA, mitindomide, mitocarcin, mitocromin, mitogillin, mitoguazone, mitolactol, mitomalcin, mitomycin, mitomycin analogs, mitonafide, mitosper, mitotane, mitotoxin fibroblast growth factor-saporin, mitoxantrone. mitoxantrone hydrochloride, mofarotene, molgramostim, monoclonal antibody, human chorionic gonadotrophin, monophosphoryl lipid a / myobacterium cell wall SK, mopidamol, multiple drug resistance gene inhibitor, multiple tumor suppressor 1 -based therapy, mustard anticancer agent, mycaperoxide B, mycobacterial cell wall extract, mycophenolic acid, myriaporone, n-acetyldinaline, nafarelin, nagrestip, naloxone / pentazocine, napavin, naphterpin, nartograstim, nedaplatin, nemorubicin, neridronic acid, neutral endopeptidase, nilutamide, nisamycin, nitric oxide modulators, nitroxide antioxidant, nitrullyn, nocodazole, nogalamycin, n-substituted benzamides, O6-benzylguanine, octreotide, okicenone, oligonucleotides, onapristone, ondansetron, oracin, oral cytokine inducer, ormaplatin, osaterone, oxaliplatin, oxaunomycin, oxisuran, paclitaxel, paclitaxel analogs, paclitaxel derivatives, palauamine, palmitoylrhizoxin, pamidronic acid, panaxytriol, panomifene, parabactin, pazelliptine, pegaspargase, peldesine, peliomycin, pentamustine, pentosan polysulfate sodium, pentostatin, pentrozole, peplomycin sulfate, perflubron, perfosfamide, perillyl alcohol, phenazinomycin, phenylacetate, phosphatase inhibitors, picibanil, pilocarpine hydrochloride, pipobroman, piposulfan, pirarubicin, piritrexim, piroxantrone hydrochloride, placetin A, placetin B, plasminogen activator inhibitor, platinum complex, platinum compounds, platinum-triamine complex, plicamycin, plomestane, porfimer sodium, porfiromycin, prednimustine, procarbazine hydrochloride, propyl bis-acridone, prostaglandin J2, prostatic carcinoma antiandrogen, proteasome inhibitors, protein A-based immune modulator, protein kinase C inhibitor, protein tyrosine phosphatase inhibitors, purine nucleoside phosphorylase inhibitors, puromycin, puromycin hydrochloride, purpurins, pyrazofurin, pyrazoloacridine, pyridoxylated hemoglobin polyoxyethylene conjugate, RAF antagonists, raltitrexed, ramosetron, RAS farnesyl protein transferase inhibitors, RAS inhibitors, RAS-GAP inhibitor, retelliptine demethylated, rhenium RE 186 etidronate, rhizoxin, riboprine, ribozymes, RH retinamide, RNAi, rogletimide, rohitukine,STDU2-44870.601romurtide, roquinimex, rubiginone Bl, ruboxyl, safingol, safingol hydrochloride, saintopin, sarcnu, sarcophytol A, sargramostim, SDI 1 mimetics, semustine, senescence derived inhibitor 1, sense oligonucleotides, signal transduction inhibitors, signal transduction modulators, simtrazene, single chain antigen binding protein, sizofiran, sobuzoxane, sodium borocaptate, sodium phenylacetate, solverol, somatomedin binding protein, sonermin, sparfosate sodium, sparfosic acid, sparsomycin, spicamycin D, spirogermanium hydrochloride, spiromustine, spiroplatin, splenopentin, spongistatin 1, squalamine, stem cell inhibitor, stem-cell division inhibitors, stipiamide, streptonigrin, streptozocin, stromelysin inhibitors, sulfinosine, sulofenur, superactive vasoactive intestinal peptide antagonist, suradista, suramin, swainsonine, synthetic glycosaminoglycans, talisomycin, tallimustine, tamoxifen methiodide, tauromustine, tazarotene, tecogalan sodium, tegafur, tellurapyrylium, telomerase inhibitors, teloxantrone hydrochloride, temoporfin, temozolomide, teniposide, teroxirone, testolactone, tetrachlorodecaoxide, tetrazomine, thaliblastine, thalidomide, thiamiprine, thiocoraline. thioguanine, thiotepa, thrombopoietin, thrombopoietin mimetic, thymalfasin, thymopoietin receptor agonist, thymotrinan, thyroid stimulating hormone, tiazofurin, tin ethyl etiopurpurin, tirapazamine, titanocene dichloride, topotecan hydrochloride, topsentin, toremifene, toremifene citrate, totipotent stem cell factor, translation inhibitors, trestolone acetate, tretinoin, triacetyluridine, triciribine, triciribine phosphate, trimetrexate, trimetrexate glucuronate, triptorelin, tropisetron, tubulozole hydrochloride, turosteride. tyrosine kinase inhibitors, tyrphostins, UBC inhibitors, ubenimex, uracil mustard, uredepa, urogenital sinus-derived growth inhibitory factor, urokinase receptor antagonists, vapreotide, variolin B, velaresol, veramine, verdins, verteporfin, vinblastine sulfate, vincristine sulfate, vindesine, vindesine sulfate, vinepidine sulfate, vinglycinate sulfate, vinleurosine sulfate, vinorelbine, vinorelbine tartrate, vinrosidine sulfate, vinxaltine, vinzolidine sulfate, vitaxin, vorozole, zanoterone, zeniplatin, zilascorb, zinostatin, zinostatin stimalamer, and zorubicin hydrochloride, as well as salts, homologs, analogs, derivatives, enantiomers and / or functionally equivalent compositions thereof.
[0138] Other examples of agents useful in the treatment of cancer include, but are not limited to, one or more of Ributaxin, Herceptin, Quadramet, Panorex, IDEC-Y2B8, BEC2, C225, Oncolym, SMART M195, ATRAGEN, Ovarex, Bexxar, LDP-03, ior t6, MDX-210, MDX-11, MDX-22, OV103. 3622W94, anti-VEGF, Zenapax, MDX-220, MDX-447, MELIMMUNE-2, MELIMMUNE-1, CEACIDE, Pretarget, NovoMAb-G2, TNT, Gliomab-H, GNI-250, EMD-STDU2-44870.60172000, LymphoCide, CMA 676, Monopharm-C, 4B5, ioregf r3, ior c5, BABS, anti-FLK-2, MDX-260, ANA Ab, SMART 1D10 Ab, SMART ABL 364 Ab and ImmuRAIT-CEA.
[0139] The method described herein also contemplates the enhanced ability to deliver therapeutic antibodies to a subject across the blood-brain barrier. Antibodies can be prepared from the intact polypeptide or fragments containing peptides of interest as the immunizing agent. A preferred antigenic polypeptide fragment is 15-100 contiguous amino acids of protein antigen of interest. In one embodiment, the peptide is located in a non-transmembrane domain of the polypeptide, e.g., in an extracellular or intracellular domain. An exemplary antibody or antibody fragment binds to an epitope that is accessible from the extracellular milieu and that alters the functionality of the protein. In certain embodiments, the antibodies contemplated recognize and are specific for one or more epitopes of a protein antigen of interest. A therapeutically useful antibody includes a “humanized” monoclonal antibody. Humanized monoclonal antibodies are produced by transferring mouse complementarity determining regions from heavy and light variable chains of the mouse immunoglobulin into a human variable domain, then substituting human residues into the framework regions of the murine counterparts. The use of antibody components derived from humanized monoclonal antibodies obviates potential problems associated with immunogenicity of murine constant regions. A therapeutically effective amount of an antibody as disclosed herein relates generally to the amount needed to achieve a therapeutic objective. This may be a binding interaction between the antibody and its target antigen that, in certain cases, interferes with the functioning of the target, and in other cases, promotes a physiological response. The amount required to be administered will furthermore depend on the binding affinity of the antibody for its specific antigen, and will also depend on the rate at which an administered antibody is depleted from the free volume of the subject to which it is administered. The dosage ranges for the administration of monoclonal antibodies are large enough to produce the desired effect, and will vary with age, condition, weight, sex, age and the extent of the condition to be treated, and can readily be determined by one skilled in the art. Common ranges for therapeutically effective dosing of an antibody or antibody fragment may be, by way of nonlimiting example, from about 0.1 mg / kg body weight to about 2000 mg / kg body weight. Common dosing frequencies may range, for example, from twice daily to once a week. The monoclonal antibodies can be administered intravenously, intraperitoneally, intramuscularly, and / or subcutaneously.STDU2-44870.601
[0140] The method also relates to the administration of immunoconjugates comprising an antibody conjugated to a chemical agent, or a radioactive isotope (i.e., a radioconjugate) for administration to the brain using the methods of the invention. Conjugates of the antibody and cytotoxic agent are made using a variety of bifunctional protein-coupling agents such as N-succinimidyl-3-(2-pyridyldithiol) propionate (SPDP), iminothiolane (IT), bifunctional derivatives of imidoesters (such as dimethyl adipimidate HCL), active esters (such as disuccinimidyl suberate), aldehydes (such as glutaraldehyde), bis-azido compounds (such as bis (p-azidobenzoyl) hexanediamine), bis-diazonium derivatives (such as bis-(p-diazoniumbenzoyl)-ethylenediamine), diisocyanates (such as tolyene 2,6-diisocyanate), and bis-active fluorine compounds (such as 1,5-difluoro-2,4-dinitrobenzene). For example, a ricin immunotoxin can be prepared as described in Vitetta et al., Science, 238: 1098 (1987). Carbon- 14-labeled l-isothiocyanatobenzyl-3-methyldiethylene triaminepentaacetic acid (MX-DTPA) is an exemplary chelating agent for conjugation of radionucleotide to the antibody. See WO94 / 11026.
[0141] In some embodiments, the at least one therapeutic agent can be small molecule therapeutic agent. In other embodiments, the therapeutic agent can be a non-small molecule therapeutic agent, such as a biologic. Therapeutic agents can include, but are not limited to, gene therapy agents, proteins (including, but not limited to, natural proteins, recombinant therapeutic proteins, antibodies, and the like), sugars, nucleic acids (including, but not limited to, natural nucleic acids, recombinant nucleic acids, vectors, and the like) and combinations of the same. Vectors can include, but are not limited to, plasmids, viral vectors, cosmids, and artificial chromosomes. In some embodiments, the therapeutic agent can include a polynucleotide. In some embodiments, the therapeutic agent can include a recombinant polynucleotide. In some embodiments, the therapeutic agent can include a vector comprising a recombinant polynucleotide. Viral vectors can include, but are not limited to, recombinant retroviruses, recombinant lentiviruses, recombinant adenoviruses, and recombinant adeno-associated viruses. In some embodiments the therapeutic agent can specifically include an adeno-associated virus (AAV) vector. While not intending to be bound by theory, it is believed that AAV vectors can be beneficial because AAV is highly efficient at transducing CNS cells, AAV vectors have demonstrated long-term (>8 years) expression in the CNS, and AAV vectors have a small viral capsids with a diameter of 20 to 25 nanometers allowing better passage within the brain extracellular space. In addition, wild-type AAV is not known to cause disease and the transgene delivered from an AAV vector generally does not integrate intoSTDU2-44870.601the host genome, which reduces concern of carcinogenesis. In some embodiments, the therapeutic agent can include at least one selected from the group of proteins (including recombinant proteins and antibodies), anti-sense RNA, siRNA, and RNAi. In some embodiments, the therapeutic agent comprises an antibody.
[0142] It should be appreciated by the person skilled in the art that the at least one therapeutic agent may be present as a pharmaceutically acceptable salt, a pharmaceutically acceptable solvate, or as a prodrug.ExamplesGlycocalyx-binding probes undergo cellular internalization
[0143] To assess the capacity of glycocalyx-binding proteins to mediate cellular uptake in brain endothelial cells, we screened a panel of fluorescein (FL)-conjugated probes, including mucinbinding protein (StcEE447D) and several plant lectins commonly used to label cell surface glycans. Following 30-minute incubations in bEnd.3 mouse brain endothelial cells these probes displayed a broad range of internalization efficiencies and subcellular localization patterns (Fig.1B-C). Notably, StcEE447D-FL, wheat germ agglutinin (WGA-FL), and concanavalin A (ConA-FL) were robustly internalized, whereas Sambucus nigra agglutinin (SNA-FL), Vicia villosa agglutinin (VVA-FL), and peanut agglutinin (PNA-FL) showed minimal to no uptake. Internalization efficiency did not correlate with the molecular weights or isoelectric points of glycocalyx-targeting probes. Furthermore, despite overlapping glycan specificities between probes, these glycocalyx-binding proteins exhibited markedly different uptake efficiencies and intracellular distributions, suggesting that additional physicochemical or structural properties influence endocytosis.
[0144] WGA and ConA have previously been reported to internalize via receptor-mediated endocytosis in various cell types, including epithelial and endothelial cells, and have been employed in drug targeting applications (3-8). In bEnd.3 cells, both lectins exhibit strong perinuclear punctate signal, consistent with receptor-mediated endocytosis and trafficking through the endolysosomal pathway (Fig. ID). Interestingly, StcEE447D-FL also binds and internalizes efficiently into bEnd.3 cells but displays a diffuse intracellular punctate distribution, suggestingSTDU2-44870.601that StcEE447D may engage a different internalization route or trafficking mechanism. Overall, these results highlight the value of glycocalyx-binding probes to serve as shuttles for cargo transport into brain endothelial cells, the first cellular barrier to BBB penetration. Based on its uptake efficiency, distinctive trafficking profile, and lack of acute toxicity, we selected StcEE447D a candidate for further development and refer to this engineered mucin-binding shuttle as StcE-derived Mucin Shuttle 1, or SMS 1.SMS1 mediates cargo transport into the brain
[0145] We next assessed the ability of SMS1 to mediate transcytosis of mCherry across the BBB and enter different brain cell types in vivo. We administered 5 mg / kg of mCherry-SMS1 or an equimolar dose of unconjugated mCherry intravenously into mice and evaluated brain uptake following transcardial perfusion at multiple time points up to 48 hours post-injection (Fig. 2A). Flow cytometry analysis revealed that SMS1 significantly enhanced mCherry delivery into brain endothelial and parenchymal cells at both 24- and 48-hours post-injection compared to unconjugated mCherry (Fig. 2B). These findings were corroborated by immunofluorescence imaging, which showed mCherry-SMS 1 displaying a time-dependent pattern of internalization, with a strong vascular signal at 2 hours post-injection, transitioning to widespread, punctate signal within the blood vessels and brain parenchyma by 6 hours, which further intensified throughout the parenchyma at 24 hours (Fig. 2C-D). In contrast, mice treated with unconjugated mCherry showed no detectable mCherry signal in the brain. These observations indicate that SMS1 facilitates progressive transcytosis and dispersion of cargo in the brain over time. Co- staining with cell type-specific markers confirmed that mCherry-SMS 1 was internalized by multiple brain cell types, including microglia, neurons, and astrocytes (Fig. 2E-G).
[0146] To elucidate the internalization mechanism of SMS1, we performed subcellular colocalization experiments in bEnd.3 cells. SMS1 exhibited strong colocalization with caveolin-1 (CAV1), a marker of caveolae, and weaker colocalization with clathrin heavy chain, suggesting a preference for caveolae-mediated uptake (Fig. 7a-b). Additionally, we observed robust colocalization with endosomal and lysosomal markers, indicating subsequent trafficking through the endolysosomal pathway (Fig. 7b). Pharmacological inhibition studies further supported this mechanism, with caveolae-disrupting agents significantly reducing mCherry-SMS 1 internalization, whereas inhibitors of clathrin-mediated endocytosis and micropinocytosis had noSTDU2-44870.601detectable effect on internalization (Fig. 7c-d). Together, these finding suggest that mCherry-SMS 1 binds mucin proteins on the cell surface and enters endothelial cells primarily through caveolae-dependent endocytosis and is at least partially trafficked through the endolysosomal system (Fig.7e), although an understanding the mechanism is not necessary to practice the invention and the invention is not limited to any particular mechanisms of action.The C-terminal domain mediates SMS1 internalization
[0147] To improve the utility of SMS 1 as a brain shuttle, we sought to engineer smaller domain variants of SMS1 that retained effective trafficking properties. SMS1 is an enzymatically inactive mucinase derived from E. coli that exhibits high binding specificity for mucins (11-12). The full-length protein comprises three globular domains and has a molecular weight of ~98kDa, which is relatively large for a protein shuttle. Protein shuttles of larger molecular size can limit cargo capacity, increase immunogenicity risk, and impact biodistribution. To identify an exemplary minimal functional unit useful for cellular uptake, we generated SMS 1 deletion constructs lacking either the C-terminal domain (SMS 1 AC) or the intervening INS region (SMS1AINS), both of which have been previously implicated in substrate recognition and binding (12, 13) (Fig. 3A-B and fig. 11). In internalization assays using bEnd.3 cells, SMS1AINS maintained robust uptake, whereas SMS 1 AC exhibited a complete loss of binding and internalization, indicating that the C-terminal domain is important for these functions (Fig. 3C-D). To test whether the C-terminal domain alone was sufficient for delivery, we generated an mCherry fusion to the isolated C-terminal domain, termed mCherry-SMS2. Remarkably, mCherry-SMS2 demonstrated efficient internalization into both mouse and human brain endothelial cells, comparable to full-length SMS1 (Fig. 3C-D and fig. S2B-C).
[0148] Binding affinity assays in K562 cells demonstrated similar affinity of mCherry-SMS 1 and mCherry-SMS2 in the middle nanomolar range (Kd = 364 and 265 nM, respectively) (Fig. 11). Importantly, binding of both SMS constructs was mucin-dependent, as enzymatic removal of mucins significantly reduced mCherry signal. Mechanistically, mCherry-SMS2 colocalizes more strongly with CAV1 compared to CLTC, and mCherry-SMS2 punctate signal was significantly reduced in CAV1 -knockout (KO) bEnd.3 cells, supporting a caveolae-mediated cellular entry mechanism (Fig. 11). These findings establish SMS2, at ~11 kDa, as a compact and efficient mucin-binding module sufficient to recapitulate the cellular uptake properties of full-length SMS 1.STDU2-44870.601SMS2 functions as an effective brain shuttle in vivo
[0149] We next compared the in vivo brain delivery efficiency of SMS1 domain variants following intravenous injection in mice. At 24 hours post-injection, mCherry-SMS 1, mCherry -SMS1 A INS, and mCherry-SMS2 all demonstrated robust brain uptake, whereas mCherry-SMS1 A C and unconjugated mCherry showed no detectable signal, mirroring the observations in brain endothelial cells in vitro (Fig. 3E). Quantification of mCherry levels in brain hemispheres by ELISA revealed similar levels of brain uptake between SMS1 and SMS2 constructs and negligible uptake of unconjugated mCherry (Fig. 3F). To quantify vascular versus parenchymal distribution of SMS constructs, we used vascular depletion of brain tissues and confirmed effective depletion of brain endothelial cell marker CD31 from parenchymal fractions (Fig. 12). mCherry-SMS2 showed less vascular retention compared to mCherry-SMS1 but similar levels of brain parenchymal delivery at 48 hours post-injection (Fig. 3G-H). Flow cytometry analysis of dissociated brain tissue confirmed cellular uptake of mCherry-SMS2 into key brain cell types, including brain endothelial cells, neurons, and microglia, supporting its use for therapeutic delivery applications (Fig. 31).
[0150] We additionally examined the distribution of SMS 1 and SMS2 constructs in peripheral organs and plasma. mCherry-SMS 1 displayed strong signal in liver hepatocytes and Kupffer cells, whereas mCherry-SMS2 exhibited more moderate liver uptake over unconjugated mCherry. Both SMS constructs exhibited minimal parenchymal uptake in the heart and kidney compared to unconjugated mCherry (Fig. 8). Overall, SMS2 exhibited lower accumulation in the selected peripheral organs than SMS1, suggesting a more favorable brain-to-periphery delivery profile. Additionally, plasma pharmacokinetic (PK) analysis revealed extended circulation half-lives for both mCherry-SMS 1 (tl / 2 = 4.4 h) and mCherry-SMS2 (tl / 2 = 4.8 h) compared to unconjugated mCherry (tl / 2 = 1.0 h) (Fig. 31). Given that mCherry-SMS2 is approximately one-third of the size of mCherry-SMS 1, the longer half-life of mCherry-SMS2 may reflect its higher binding affinity to cell surfaces which may potentially prolong systemic retention. Together, these results demonstrate that SMS2 retains the brain delivery efficiency of full-length SMS1, while exhibiting reduced peripheral tissue uptake. Its compact size, broad brain distribution, uptake into major brain cell types, and favorable pharmacokinetic profile establish SMS2 as an efficient platform for targeted CNS drug delivery.STDU2-44870.601Anti-BACEl antibody delivery and therapeutic efficacy in AD mouse model
[0151] Antibodies are attractive therapeutic agents due to their high specificity, tunable structure, and extended half-life, however, their clinical application for CNS diseases is severely limited by their large size and poor permeability across the BBB. To assess the ability of SMS2 to effectively deliver antibody cargo into the brain with therapeutic activity, we engineered SMS2-fused versions of a human monoclonal antibody targeting BACE1, a transmembrane protease involved in amyloid beta (A ) generation and a well-established therapeutic target in AD (3, 13, 14). Although BACE1 inhibitors have underperformed clinically, insufficient BBB penetration remains a potential contributing factor to their limited efficacy. Importantly, for brain shuttle evaluation, BACE1 targeting offers the advantage of clear pharmacodynamic (PD) biomarkers, such as brain Ap peptide levels, to assess target engagement.
[0152] We generated SMS2 fusions to the C-terminus of the human anti-BACE1 antibody (αBACE1) and tested internalization efficacy in bEnd.3 cells (Fig. 4A). Unconjugated αBACE1 showed no detectable binding or internalization, consistent with its limited ability to engage and internalize into brain endothelial cells (Fig. 4B-C). However, αBACE1-SMS2 exhibited significantly higher levels of binding and internalization and demonstrated a requirement for cell surface mucins for engagement. We next evaluated brain delivery in vivo by injecting mice intravenously with αBACE1 or αBACE1-SMS2 and assessed human IgG (hlgG) signal in brain slices by immunofluorescence staining. αBACE1 alone resulted in minimal brain uptake, with faint signal restricted to periventricular and meningeal regions (Fig. 4D). In contrast, αBACE1-SMS2 showed widespread uptake across brain regions, indicating robust BBB transport and parenchymal distribution.
[0153] We next assessed therapeutic efficacy in the 5XFAD mouse model of AD, which exhibits early, aggressive amyloid pathology driven by transgenic overexpression of human amyloid precursor protein (APP) and presenilin 1 (PSI) with five familial AD mutations under the mThyl promoter. In this model, BACE1 initiates amyloidogenic Ap production by cleaving APP into sAPPp and membrane-bound C99, which is subsequently processed by y-secretase into Ap peptides with a strong bias toward the pathogenic Ap42 isoform. Using ELISA quantification of hlgG in brain lysates, we demonstrate that SMS2 effectively shuttles αBACE1 into the brains of 5XFAD mice, with approximately 475 pg of hlgG per mg of brain tissue detected 48 hours afterSTDU2-44870.60125 mg / kg αBACE1 -SMS2 injection, whereas unconjugated αBACE1 was undetectable (Fig. 4E-F). Importantly, treatment with αBACE1-SMS2 led to a significant reduction in brain Aβ42 levels at 48 hours post-injection relative to αBACE1 alone, indicating effective B ACE1 inhibition in vivo (Fig. 4G). Additionally, plasma Ap42 and Aβ40 levels were reduced up to 24 hours post-injection in αBACE1-SMS2-treated mice compared to unconjugated αBACE1-treated mice, further supporting enhanced target engagement (Fig. 4H-I). These findings establish SMS2 as a potent brain delivery platform for therapeutic antibodies, facilitating high brain penetrance and functional efficacy in relevant CNS disease models.Progranulin delivery into GRN- / - mouse brains
[0154] To further assess the versatility of SMS2 as a brain delivery platform, we evaluated its capacity to transport human progranulin (hPGRN) into the CNS. PGRN is a secreted glycoprotein essential for proper lysosomal function and brain homeostasis. Loss-of-function mutations in the GRN gene, which encodes PGRN, account for approximately 10-15% of familial FTD cases. These mutations often result in haploinsufficiency and are associated with lysosomal dysfunction, glial activation, and progressive cortical neurodegeneration. While recombinant PGRN exhibits poor BBB penetration, emerging strategies that enhance CNS delivery of PGRN have demonstrated potential to restore lysosomal function and ameliorate FTD-related phenotypes (16-18).
[0155] To preserve endogenous trafficking and lysosomal targeting, we fused SMS2 to the N-terminus of hPGRN, maintaining its native C-terminal lysosomal sorting motifs (Fig. 5A-B). In bEnd.3 cells, SMS2-hPGRN displayed robust mucin-dependent internalization, whereas unconjugated hPGRN exhibited minimal uptake (Fig. 5C-D). Grn- / - mice, which recapitulate key age-dependent pathological features of GRN deficiency, including lysosomal dysfunction, neuroinflammation, and age-dependent neuronal loss, were used to evaluate in vivo efficacy of brain delivery. Mice were treated with saline, 15 mg / kg of SMS2-hPGRN, or an equimolar dose of unconjugated hPGRN, and bis(monoacylglycero)phosphate (BMP) levels in brain hemispheres were quantified by lipidomics (Fig. 5E). BMP depletion is an early hallmark of lipid dysregulation in FTD-GRN and serves as a sensitive readout of lysosomal health. Several key genotypedependent BMP species, including BMP(18: 1 / 18:1) and BMP(22:6 / 22:6), are reduced by -50-70% in Grn - / - brains relative to wild-type as early as two months of age. While unconjugated hPGRNSTDU2-44870.601administration did not increase in BMP levels in Grn- / - mice, SMS2-hPGRN treatment significantly improved BMP levels, including a 56% increase in BMP(18: 1 / 18:1) and a 60% increase in BMP(22:6 / 22:6), relative to saline-treated knockout mice. These findings demonstrate that SMS2-hPGRN enhances lysosomal function and facilitates correction of GRN-deficiency-associated lipid abnormalities (Fig. 5F). More broadly, they highlight the modularity and therapeutic potential of SMS2 as a brain delivery platform, showing that it can be flexibly fused to either terminus of cargo proteins, thereby preserving critical cargo functional domains and enabling customizable strategies for CNS -targeted delivery.EXPERIMENTALCell culture
[0156] All cells were maintained at 37°C and 5% CO2. The mouse brain endothelial cell line bEnd.3 (ATCC, CRL-2299) was cultured in high glucose DMEM (Thermo Fisher Scientific, 10567022) supplemented with 10% fetal bovine serum (FBS) and 1% penicillin / streptomycin. Human brain endothelial cell line hCMEC / D3 (Sigma, SCC066) was cultured in EndoGRO-MV Complete Culture Media (Sigma, SCME004) according to manufacturer recommendations. Human primary brain microvascular endothelial cells (Cell Systems, ACBRI 376) were cultured in Complete Classic Media with Serum (Cell Systems, 4Z0-500) according to manufacturer’s recommendations. Neuro2A cells (ATCC, CCL-131) were cultured in EMEM (ATCC, 30-2003) supplemented with 10% fetal bovine serum (FBS) and 1% penicillin / streptomycin.Animals
[0157] C57BL / 6 mice (Jackson Laboratory, stock #000664), Grn - / - mice (Jackson Laboratory, stock #013175), and 5XFAD mice (Jackson Laboratories, stock #034848) were obtained from Jackson Laboratory. Mice were housed in a 12-h light / dark cycle, temperature (20-22°C) and humidity controlled environment and provided ad libitum access to food and water. Both male and female mice were used, depending on availability from the vendor or in-house colony. Specifically, 3- to 4-month-old male mice were used in experiments involving mCherry constructs; 2.5-month-old female 5XFAD mice were used for anti-BACE1 antibody delivery studies; and 3-month-old male and female Gm / mice were used in progranulin delivery studies, with data from both sexes pooled due to the absence of sex-dependent differences. All animal care and procedures compliedSTDU2-44870.601with the Animal Welfare Act and were in accordance with institutional guidelines and approved by the institutional administrative panel of laboratory animal care at Stanford University.Cloning
[0158] All shuttle constructs were cloned from a pET28b-StcEE447Dplasmid19using Q5 site-directed mutagenesis (New England Biolabs). The amino acid sequence for mCherry and progranulin was reverse translated and optimized for expression in E. coli K12 with the IDT Codon Optimization Tool for cloning. The anti-BACE1 antibody and anti-TfR Fab sequences were gathered from previous publications13 15. Constructs comprising PGRN and the anti-BACE1 antibody were optimized and cloned for mammalian cell expression by Genscript.Protein purification
[0159] BL21(DE3) E.coli cells (New England BioLabs) or ClearColi BL21(DE3) electrocompetent cells (Lucigen) cells were transformed with sequence-confirmed plasmids and grown in sterile LB-Miller broth with 30 μg / ml kanamycin at 37 °C and 250 rpm. Cultures were induced at an optical density of 0.6-0.8 with 0.4 mM isopropyl-β-D-1-thiogalactopyranoside (IPTG) and grown overnight at 20 °C and 250 rpm. Cells were centrifuged at 6,000g for 10 min and lysed in 20 mM HEPES (pH 7.5) and 500 mM NaCl with a probe tip sonicator. Lysates were clarified by centrifuging at 11,000g for 10 min and filtered through a low-protein-binding 0.22-μm polyethersulfone membrane vacuum filter bottle (Corning). Lysates were applied to 3-4 ml of Ni-NTA agarose (Qiagen) per liter of bacterial culture, washed with 200 ml of 20 mM HEPES (pH 7.5), 500 mM NaCl and 20 mM imidazole and eluted with 20 ml of 20 mM HEPES (pH 7.5), 500 mM NaCl and 250 mM imidazole per liter of culture. Extracted proteins were buffer exchanged into cold 2X PBS with Zeba Spin desalting columns (7,000-Da molecular weight cutoff (MWCO)) and further purified by size exclusion chromatography using a Superdex 200 Increase 10 / 300 GL Column (Cytiva Life Sciences) in 2X PBS, pH 7.4. Protein concentration was determined via NanoDrop, and protein purity was determined by SDS-PAGE. Proteins were run through Pierce high-capacity endotoxin removal columns (Thermo Fisher Scientific) at least two times, following the manufacturer’s instructions. Endotoxin levels were tested using a HEK-Blue LPS detection kit 2 (InvivoGen) according to the manufacturer’s recommendations. All endotoxin levels were confirmed to be below K / M for the maximum dose used in vivo, where K is 5 EU kg-STDU2-44870.6011, and M is the dose of the protein / formulation of interest within a 1 -h period. Purified, endotoxin-free protein aliquots were stored at -80 °C and thawed and stored at 4 °C before experiments.Cell surface flow cytometry-based binding assays
[0160] HeLa cells (4 x 105— 5 x 105cells) were added to each well of a V-bottom 96-well plate and washed three times with cold FACS buffer containing 2 mM EDTA. Cells were treated with StcE mucinase in cold FACS buffer containing 2 mM EDTA and 0.1% benzonase for 30 min on ice, washed three times with FACS buffer with 2mM EDTA and stained with FITC-anti-His (clone GG11-8F3.5.1; Miltenyi Biotec) for 30 min on ice. Cells were washed three times with FACS buffer with 2 mM EDTA and stained with 5 nM Sytox Blue in FACS buffer with 2 mM EDTA for 20 min. Approximately 10,000 live single cells were analyzed using a MACSQuant Analyzer 10 flow cytometer (Miltenyi Biotec).ColabFold modeling
[0161] Protein sequences for mCherry-StcEE447D, mCherry-StcEE447DΔINS, mCherry-StcEE447DΔC. and mCherry-Cdom were used as input for ColabFold20. The predicted structure for SMS1 variants aligned well with the crystal X-ray structure determined by Yu et al. (Neurother. 10 (2013)) based on root mean squared deviation (RMSD) < 1.5. Molecular diagrams were generated using Pymol.In vitro cellular internalization assays
[0162] Cells were plated on round coverslips (EMS, 72196-12) in a 24-well plate about 16-20h before using. StcE treatment was performed using 1 nM StcE for Ih at 37°C. For endocytosis inhibitor experiments, the inhibitors were added for 20 min before co-incubation of shuttle constructs. The follow final concentrations of inhibitors were used: 60U / mL nystatin (Sigma, N9150), 50 μM genistein (Sigma, PHR1859), 1 μg / mL filipin III (Sigma, F4767), 5 mM methyl-β-cyclodextrin (Sigma, C4555), 25 pM monensin (Abeam, abl93381), 10 pM chlorpromazine (Sigma. C8138), 50 nM bafilomycin (Cell Signaling, 54645), and 100 μM EIPA (R& D systems, 3378). For bend.3 targeted knockout (KO) experiments, KO cell lines were generated using Cas9 ribonucleoprotein (RNP) electroporation with guide sequences designed via Synthego. Shuttle constructs were added at 250nM, unless otherwise noted, for 30 min and then washed 3 times withSTDU2-44870.601cold PBS before fixation in 4% paraformaldehyde for 15 min. Cells were washed 3 times with PBS for 5 minutes and blocked in 3% normal donkey serum with 0.3% Triton X-100 in PBS for 1 h at room temperature. Cells were incubated at room temperature in blocking solution with the following primary antibodies for 1.5 h: goat anti-CD31 (1:100, R& D, AF3628), rabbit anti-CAVl (1:100, Cell Signaling Technologies, 3267S), mouse anti-CLTC (1:100, Thermo, MAI-065), rabbit anti-mCherry (1:100, Cell Signaling Technologies, 43590), rat anti-mCherry (1:100. Thermo, M11217), goat anti-RAB5 (1:100, LSBio, LS-B12415-300), mouse anti-EEAl (1:100, Cell Signaling, 48453S), mouse anti-RAB7 (1:100, Cell Signaling, 95746S), rabbit anti-RABll (1:100, Cell Signaling, 5589S), goat anti-golgi protein 58k (1:100, Thermo PAI-9000), rat anti-LAMPl (1:100, Thermo, 14-1071-82), and mouse anti-V5 tag (1:100, BioRad, MCA1360). Cells were subsequently washed three times with PBS. stained with the appropriate Alexa Fluor-conjugated secondary antibodies (1:250, Thermo) for 1 h at room temperature, washed three times again, mounted, and coverslipped with Vectashield Hardset Antifade Mounting Medium with DAPI (Vector Labs, H-1500-10) or ProLong Gold Antifade Mountant (Thermo Fisher Scientific, P36934). Imaging was performed on a confocal laser-scanning microscope (Zeiss LSM880), and images were analyzed using ImageJ.In vivo immunofluorescence analysis
[0163] Mice were injected with retro-orbitally with constructs at the specified doses. Mice were anesthetized with Avertin and perfused with PBS before tissue extraction. Tissues were fixed in 4% PFA at 4°C overnight and preserved in 30% sucrose in PBS for at least 24 h before sectioning. Tissues were sectioned into 40 pm slices using a microtome (Leica), blocked in 3% normal donkey serum with 0.3% Triton X-100 in TBS-T for 1.5 h at room temperature, and then incubated at 4°C overnight with the following primary antibodies: goat anti-CD31 (1:100, R& D, AF3628), goat anti-Ibal (1:100, Abeam, ab5076), mouse anti-NeuN (1:200, Sigma, MAB377), chicken anti-GFAP (1:1000, Thermo, PAI-10004), rabbit anti-mCherry (1:100, Cell Signaling Technologies, 43590), and rat anti-mCherry (1:100, Thermo, M11217). The following day, slices were washed three times with TBS-T, stained with the appropriate Alexa Fluor-conjugated secondary antibodies (1:250, Thermo Fisher Scientific) for 2 h at room temperature, washed three times again, mounted, and coverslipped with Vectashield Hardset Antifade Mounting Medium with DAPI (Vector Labs,STDU2-44870.601H- 1500- 10). Imaging was performed on a confocal laser-scanning microscope (Zeiss LSM880), and images were analyzed using ImageJFlow cytometry quantification of mCherry in brains
[0164] Following anesthetization of mice with Avertin and PBS perfusions, brains were extracted and prepared for flow cytometry as previously described21. Briefly, hemibrains were minced and digested with a neural dissociation kit (Miltenyi, 130-092-628) according to manufacturer’s instructions. Brain homogenates were filtered through a 100 μM strainer and then centrifuged in 0.9M sucrose to remove myelin. Samples were blocked for 10 min with Fc preblock (CD16 / CD32, BD, 553141) and stained for 30 min with rat anti-CD31-FITC (1:100, Biolegend, 102406) and rat anti-CD45-PE / Cy7 (1:200. Biolegend, 103114). Live cells were identified using Sytox Blue viability dye (1:1000, Thermo Fisher Scientific, S34857). Flow cytometry analysis was performed on a Sony SH800S sorter, and data were analyzed using FlowJo software (TreeStar). mCherry signal was quantified in live, singlet cells for each sample. mCherry signal was quantified in live, singlet cells for each sample with gating of brain endothelial cells (CD31+), neurons (CD90+), and microglia (CDllb+) when applicable.Vascular depletion and validation
[0165] Brain samples were homogenized in HBSS using a Dounce homogenizer as previously described (Buff et al., Bio-Protocols, Isolation and imaging of microvessels from brain tissue (2025)). Homogenized tissue was centrifuged at 1000g for 10 min at 4°C to pellet microvessels and cells. The supernatant was saved as the non-cellular associated fraction on ice. The cell pellet was mixed with 25% dextran in HBSS and centrifuged at 4400g for 20 min at 4°C. The pellet was saved as vascular cells on ice. The supernatant was transferred to a new tube, diluted with 20mL of HBSS and centrifuged at 4400g for 20 min at 4°C. The pellet was saved as parenchymal cells on ice. Cell fractions were lysed in IX RIPA lysis buffer (Thermo) supplemented with 1x complete™ protease inhibitor cocktail (Sigma) and centrifuged at 13,000g for 15 min at 4°C. Protein concentrations were measured by BCA (Pierce) and normalized before quantification of mouse CD31 via ELISA according to manufacturer instructions (Abeam, ab204527).Tissue ELISA analysisSTDU2-44870.601
[0166] Tissues were homogenized via sonication in 1X RIPA lysis buffer (Thermo) supplemented with 1x complete™ protease inhibitor cocktail (Sigma). Lysates were centrifuged at 13,000g for 15 min at 4°C, and supernatant protein concentrations were measured by BCA (Pierce). mCherry ELISA quantification (Abeam, ab221829) was performed on mouse brain tissue and plasma according to manufacturer instructions. Human Aβ42 and Aβ40 were measured in mouse plasma and cortex samples using the V-PLEX Aβ Peptide Panel 1 (6E10; Cat# K15200E, Meso Scale Diagnostics, Rockville, MD) in a blinded manner. Assay was run according to manufacturer directions and plates were measured using the MESO QuickPlex SQ 120 instrument (Meso Scale Diagnostics). Human immunoglobulin isotyping panel 1 kit (Cat# K15203D, Meso Scale Diagnostics) was used to measure human Ig concentration in mouse cortex and blood samples in a blinded manner. Assays were run according to manufacturer directions and plates were measured using the MESO QuickPlex SQ 120 instrument (Meso Scale Diagnostics). To demonstrate specificity of the human IgG assay, human isotypes IgA and IgM were also measured and were not detected.Plasma PK / PD
[0167] For plasma PK / PD evaluation, mice were dosed intravenously with the specified construct and in-life plasma was take via saphenous vein bleeding. Blood was collected in EDTA- or heparincoated tubes and centrifuged at 2000g for 15 min at 4°C. Plasma was isolated for subsequent analysis via ELISA assays as described above.Targeted BMP lipidomics
[0168] Following PBS perfusion of mice, brains were extracted, snap-frozen on dry ice, and stored at -80 °C until further processing. Briefly, frozen left hemisphere brain tissue was homogenized in a dounce tissue homogenizer in 1 mL of potassium phosphate buffered saline (KPBS, 136 mM KC1, 10 mM KH2PO4, pH 7.4). For lipid extraction, 25 μL of homogenate were added to a microcentrifuge tube containing 1 mL of chloroform: methanol (2:1, v / v) containing SPLASH LIPIDOMIX (750 ng / mL, Avanti) and vortexed for 1 h at 4 °C. Subsequently, 200 pL of 0.9% (w / v) NaCl solution (VWR) was added, and the mixture was vortexed again for 10 min at 4 °C and centrifuged at 3000 x g for 5 min. After centrifugation, the mixture was separated into aqueous layer (upper) and organic layer (bottom). 600 pl of organic layer were transferred into a new microcentrifuge tube and dried in speedvac until all solvent was evaporated. Dried lipids were thenSTDU2-44870.601solubilized in 50 μl of lipid reconstitution buffer (acetonitrile: isopropanol: H2O 13:6:1, v / v / v) and vortexed for 10 minutes at 4 °C. The samples were centrifuged at 20,627g for 10 min at 4°C, and 45 μl was transferred into a glass vial with inserts for mass spectrometry analysis. Lipids were separated on an Agilent RRHD Eclipse Plus C18, 2.1 x 100 mm, 1.8u-BC column with an Agilent guard holder (UHPLC Grd; Ecl. Plus Cl 8; 2.1 mm; 1.8 pm). Before mass spectrometry, the columns were connected to a 1290 LC system for lipid separation. The liquid chromatography system was linked to an 6495D Triple Quadrupole (QQQ) mass spectrometer with a liquid chromatography-electrospray ionization probe. External mass calibration was performed weekly using a QQQ standard tuning mix. The column compressor and autosampler were held at 45 °C and 4 °C, respectively. The mass spectrometer parameters included a capillary voltage of 4.4 kV in positive mode and 5.5 kV in negative mode, and the gas temperature and sheath gas flow were held at 200 °C and 275 °C, respectively. The gas flow and sheath gas flow were 10 and 11 L per min, respectively, whereas the nebulizer was maintained at 45 psi. The nozzle voltages were maintained at 500V in the positive mode and 1,000V in the negative mode. 3 μL injection volumes were used for each sample for polarity switching. A mobile phase with two distinct components (A and B) was used in the chromatographic process. Mobile phase A was a mixture of acetonitrile: water (2:3 (v / v)), whereas mobile phase B was composed of isopropanol:acetonitrile (9:1 (v / v)), both containing 0.1% formic acid and 10 mM ammonium formate. The elution gradient was earned out over a total of 16 min, with an isocratic elution of 15% B for the first minute, followed by a gradual increase to 70% of B over 3 min and then to 100% of B from 3 to 14 min. Subsequently, this was maintained from 14 to 15 min, after which solvent B was reduced to 15% and maintained for 1 min, followed by an extra 2 min for column re-equilibration. The flow rate was set to 0.400 mL / min. The QQQ was set to operate in multiple reaction monitoring (MRM) to analyze compounds of interest. Standard lipids, glycerophosphodiesters and amino acids were optimized using the MassHunter Optimizer MRM, a software used for automated method development. For most species, the two most abundant transitions were selected to detect it. Annotation and quantification of lipids were performed using Quant-My-Way (Agilent). Individual lipid species shown in the figures were validated using the Qualitative software by manually checking the peak alignment and matching the retention times and MS / MS spectra to the characteristic fragmentation compared to the standard compounds. Analyzing two transitions for the same compound and looking for similar relative response was an added validation criterion toSTDU2-44870.601ensure the correct species were identified and quantified. The MRM method and retention time were used to quantify all lipid species using the quantification software, and the raw peak areas of all species were exported to Microsoft Excel for further analysis. Raw abundances were normalized to PC (18:1 / 18:1).
[0169] Although the invention has been variously disclosed herein with reference to illustrative embodiments and features, it will be appreciated that the embodiments and features described hereinabove are not intended to limit the invention, and that other variations, modifications and other embodiments will suggest themselves to those of ordinary skill in the art, based on the disclosure herein. The invention therefore is to be broadly construed, as encompassing all such variations, modifications and alternative embodiments within the spirit and scope of the claims hereafter set forth.Shuttles:1. StcEE447D2. C domain (Cdom)3. StcEE447DAINS4. StcEE447DACCargos tested:1. Fluorescent protein (mCherry) - genetically fuseda. mCherry-StcEE447Db. mCherry-Cdomc. mCherry-StcEE447DΔINSd. mCherry-StcEE447DΔC2. Fluorophore (Fluorescein) - chemically conjugateda. StcEE447D-FL3. Antibody (anti-BACEl) - genetically fuseda. Anti-BACEl antibody-Cdom (monovalent)b. Anti-BACEl antibody-Cdom (bivalent)4. Lysosomal enzyme (Progranulin)a. Cdom-PGRNSMS1 ADNNSAIYFNTSQPINDLQGSLAAEVKFAQSQILPAHPKEGDSQPHLTSLRKSLLLVRPVKADDK TPVQVEARDDNNKILGTLTLYPPSSLPDTIYHLDGVPEGGIDFTPHNGTKKIINTVAEVNKLSDASSTDU2-44870.601GSSIHSHLTNNALVEIHTANGRWVRDIYLPQGPDLEGKMVRFVSSAGYSSTVFYGDRKVTLSVG NTLLFKYVNGQWFRSGELENNRITYAQHIWSAELPAHWIVPGLNLVIKQGNLSGRLNDIKIGAPG ELLLHTIDIGMLTTPRDRFDFAKDKEAHREYFQTIPVSRMIVNNYAPLHLKEVMLPTGELLTDMDP GNGGWHSGTMRQRIGKELVSHGIDNANYGLNSTAGLGENSHPYVVAQLAAHNSRGNYANGIQ VHGGSGGGGIVTLDSTLGNEFSHDVGHNYGLGHYVDGFKGSVHRSAENNNSTWGWDGDKK RFIPNFYPSQTNEKSCLNNQCQEPFDGHKFGFDAMAGGSPFSAANRFTMYTPNSSAIIQRFFE NKAVFDSRSSTGFSKWNADTQEMEPYEHTIDRAEQITASVNELSESKMAELMAEYAVVKVHMW NGNWTRNIYIPTASADNRGSILTINHEAGYNSYLFINGDEKVVSQGYKKSFVSDGQFWKERDVV DTREARKPEQFGVPVTTLVGYYDPEGTLSSYIYPAMYGAYGFTYSDDSQNLSDNDCQLQVDTK EGQLRFRLANHRANNTVMNKFHINVPTESQPTQATLVCNNKILDTKSLTPAPEGLTYTVNGQAL PAKENEGCIVSVNSGKRYCLPVGQRSGYSLPDWIVGQEVYVDSGAKAKVLLSDWDNLSYNRIG EFVGNVNPADMKKVKAWNGQYLDFSKPRSMRVVYK (SEQ ID N0:1)SMS2Constructs:1. mCherry: StcEE447DH is-mCherrv-GGS-StcEE447DMGSSHHHHHHSSGLVP RGSHMASVSKGEEDNMAIIKEFMRFKVHMEGSVNGHEFEIEGEGEG RPYEGTQTAKLKVTKGGPLPFAWDILSPQFMYGSKAYVKHPADIPDYLKLSFPEGFKWERVMN FEDGGVVTVTQDSSLQDGEFIYKVKLRGTNFPSDGPVMQKKTMGWEASSERMYPEDGALKG EIKQRLKLKDGGHYDAEVKTTYKAKKPVQLPGAYNVNIKLDITSHNEDYTIVEQYERAEGRHST GGMDELYKGGSGGSGGSGGSADNNSAIYFNTSQPINDLQGSLAAEVKFAQSQJLPAHPKEGDSSTDU2-44870.601His-mCherry-GGS-CdomMGSSHHHHHHSSGLVP RGSHMASVSKGEEDNMAIIKEFMRFKVHMEGSVNGHEFEIEGEGEG RPYEGTQTAKLKVTKGGPLPFAWDILSPQFMYGSKAYVKHPADIPDYLKLSFPEGFKWERVMN FEDGGVVTVTQDSSLQDGEFIYKVKLRGTNFPSDGPVMQKKTMGWEASSERMYPEDGALKG EIKQRLKLKDGGHYDAEVKTTYKAKKPVQLPGAYNVNIKLDITSHNEDYTIVEQYERAEGRHST GGMDELYKGGSGGSGGSGGSENEGCIVSVNSGKRYCLPVGQRSGYSLPDWIVGQEVYVDSG AKAKVLLSDWDNLSYNRIGEFVGNVNPADMKKVKAWNGQYLDFSKPRSMRVVYK (SEQ ID NO:4)NO:4)3. mCherry: StcEE447DAINSHis-mCherry-GGS-StcEE447DΔINSMGSSHHHHHHSSGLVP RGSHMASVSKGEEDNMAIIKEFMRFKVHMEGSVNGHEFEIEGEGEG RPYEGTQTAKLKVTKGGPLPFAWDILSPQFMYGSKAYVKHPADIPDYLKLSFPEGFKWERVMN FEDGGVVTVTQDSSLQDGEFIYKVKLRGTNFPSDGPVMQKKTMGWEASSERMYPEDGALKG EIKQRLKLKDGGHYDAEVKTTYKAKKPVQLPGAYNVNIKLDITSHNEDYTIVEQYERAEGRHST GGMDELYKGGSGGSGGSGGSADNNSAIYFNTSQPINDLQGSLAAEVKFAQSQILPAHPKEGDSYCLPVGQRSGYSLPDWIVGQEVYVDSGAKAKVLLSDWDNLSYNRIGEFVGNVNPADMKKVKAWNGQYLDFSKPRSMRVVYK (SEQ ID NO:5)4. mCherry: StcEE447DACHis-mCherry-GGS-StcEE447DACMGSSHHHHHHSSGLVP RGSHMASVSKGEEDNMAIIKEFMRFKVHMEGSVNGHEFEIEGEGEG RPYEGTQTAKLKVTKGGPLPFAWDILSPQFMYGSKAYVKHPADIPDYLKLSFPEGFKWERVMN FEDGGVVTVTQDSSLQDGEFIYKVKLRGTNFPSDGPVMQKKTMGWEASSERMYPEDGALKG EIKQRLKLKDGGHYDAEVKTTYKAKKPVQLPGAYNVNIKLDITSHNEDYTIVEQYERAEGRHST GGMDELYKGGSGGSGGSGGSADNNSAIYFNTSQPINDLQGSLAAEVKFAQSQILPAHPKEGDS QPHLTSLRKSLLLVRPVKADDKTPVQVEARDDNNkk’ii iSTDU2-44870.601SVHRSAENNNSTWGWDGDKKRFIPNFYPSQTNEKSCLNNQCQEPFDGHKFGFDAMAGGSPF5. anti-BACE1: Cdom (monovalent)Signal Peptide-BACE1 -GGS-Cdom (mono)Heavy Chain (Knob) (with Cdom) MGWSCIILFLVATATGVHSEVQLVESGGGLVQPGGSLRLSCAASGFTFLGYGIHWVRQAPGKG LEWVGWISPAGGSTDYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARGPFSPWVM DYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSG VHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTGPPCP APELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPRE EQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPGRD ELTKNQVSLWCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQ QGNVFSCSVMHEALHNHYTQKSLSLSPGGGSGGGGSGGGGSGGGGSENEGCIVSVNSGKR YCLPVGQRSGYSLPDWIVGQEVYVDSGAKAKVLLSDWDNLSYNRIGEFVGNVNPADMKKVKA WNGQYLDFSKPRSMRVVYK (SEQ ID NO:7)Heavy Chain (Hole) MGWSCIILFLVATATGVHSEVQLVESGGGLVQPGGSLRLSCAASGFTFLGYGIHWVRQAPGKG LEWVGWISPAGGSTDYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYGARGPFSPWVM DYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSG VHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTGPPCP APELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPRE EQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVCTLPPSRD ELTKNQVSLSCAVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLVSKLTVDKSRWQ QGNVFSCSVMHEALHNRFTQKSLSLSPGK (SEQ ID NO:8)Light Chain MGWSCIILFLVATATGVHSDIQMTQSPSSLSASVGDRVTITCRASQDVSTAVAWYQQKPGKAP KLLIYSASFLYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQFPTYLPTFGQGTKVEIKRT VAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDST YSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC.(SEQ ID NO:9)6. anti-BACE1: Cdom (bivalent)Signal Peptide -BACE1 -GGS-CdomHeavy Chain MGWSCIILFLVATATGVHSEVQLVESGGGLVQPGGSLRLSCAASGFTFLGYGIHWVRQAPGKG LEWVGWISPAGGSTDYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARGPFSPWVM DYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSG VHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCP PCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTK PREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSTDU2-44870.601SRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSR WQQGNVFSCSVMHEALHNHYTQKSLSLSPGGGSGGGGSGGGGSGGGGSENEGCIVSVNSG KRYCLPVGQRSGYSLPDWIVGQEVYVDSGAKAKVLLSDWDNLSYNRIGEFVGNVNPADMKKV KAWNGQYLDFSKPRSMR^Light Chain MGWSCIILFLVATATGVHSDIQMTQSPSSLSASVGDRVTITCRASQDVSTAVAWYQQKPGKAP KLLIYSASFLYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQFPTYLPTFGQGTKVEIKRT VAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDST YSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO:11)7. Cdom: PGRNSignal Peptide / His / V5-Cdom-GGS-PGRNMGWSCIILFLVATATGVHSGSSHHHHHHSSGGKPIPNPLLGLDSTENEGCIVSVNSGKRYCLPV GQRSGYSLPDWIVGQEVYVDSGAKAKVLLSDWDNLSYNRIGEFVGNVNPADMKKVKAWNGQ YLDFSKPRSMRVVYKGGSGGSGGSGGSTRCPDGQFCPVACCLDPGGASYSCCRPLLDKWP TTLSRHLGGPCQVDAHCSAGHSCIFTVSGTSSCCPFPEAVACGDGHHCCPRGFHCReferences:1 Jason, M. L. a. E. V. S. Targeting receptor- mediated transport for delivery of biologies across the blood-brain barrier. Annual Review of Pharmacology and Toxicology 55, 613-631, pmid = 25340933 (2015). https: / / doi.org / 10.1146 / annurev-pharmtox-010814-1248522 Mihalis, S. K. a. R. C. W. a. J. A. G. a. W. K. a. C. S. M. a. R. T. a. D. J. K. a. A. S. a. Brain delivery of therapeutic proteins using an Fc fragment blood-brain barrier transport vehicle in mice and monkeys. Science Translational Medicine 12, 1-14, pmid = 32461332 (2020).3 N, S. & A, M. Wheat germ agglutinin-conjugated nanoparticles for sustained cellular and lung delivery of budesonide - PubMed. Drug delivery 15 (2008 Feb).https: / / doi.org / 10.1080 / 10717540801904846STDU2-44870.6014 JC, V. & RD, B. Transcytosis of protein through the mammalian cerebral epithelium and endothelium. II. Adsorptive transcytosis of WGA-HRP and the blood-brain and brain-blood barriers - PubMed. Journal of neurocytology 22 (1993 Feb), https: / / doi.org / 10.1007 / BF01181571 5 C, W., I, S. & L, I. Internalization of wheat germ agglutinin (WGA) by rat pancreatic cells in vivo and in vitro - PubMed. Acta histochemica 98 (1996 Apr). https: / / doi.org / 10.1016 / S0065-1281(96)80035-36 Storrie, B. Direct endocytosis of concanavalin A by motile fibroblasts. Experimental Cell Research 118 (1979 / 01 / 01). https: / / doi.org / 10.1016 / 0014-4827(79)90591-37 Welsch, U. et al. Internalization of ferritin-concanavalin A by the lactating mammary cell in vivo. Cell and Tissue Research 1984235:2235 (1984 / 02).8 Wijetunge, S. S., Wen, I., Yeh, C.-K. & Sun, Y. Wheat germ agglutinin liposomes with surface grafted cyclodextrins as bioadhesive dual-drug delivery nanocarriers to treat oral cells. Colloids and Surfaces B: Biointerfaces 185 (2020 / 01 / 01).9 Sophia, M. S. a. R. J. S. a. D. J. S. a. F. J. G. a. N. L. a. M. H. a. C. R. B. a. T. W.-C. Cerebrovascular glycocalyx degeneration promotes blood-brain bander dysfunction in aging and disease. Nature (under review) (2023).10 Roberts, R. L., Fine. R. E. & Sandra, A. Receptor-mediated endocytosis of transferrin at the blood-brain barrier. Journal of Cell Science 104 (1993 / 02 / 01).hrtps: / / doi.org / 10.1242 / jcs.104.2,52111 Angel, C. Y. Y. a. L. J. W. a. N. C. I. S. Structural insight into the bacterial mucinase StcE essential to adhesion and immune evasion during enterohemorrhagic E. coli infection. Structure 20, 707-717, pmid = 2248311712 Stacy, A. M. a. K. P. a. M. J. F. a. B. A. B. a. V. K. a. C. P. a. I. Y. a. E. C. W. a. J. The mucin-selective protease StcE enables molecular and functional analysis of human cancer- associated mucins. Proceedings of the National Academy of Sciences of the United Stales of America 116, 7278-7287, pmid = 30910957, publisher = National Academy of Sciences (2019).STDU2-44870.60113 Atwal, J. K. et al. A Therapeutic Antibody Targeting B ACE1 Inhibits Amyloid-0 Production in Vivo. Science Translational Medicine 3 (2011-05-25).https: / / doi.org / 10.1126 / scitranslmed.300225414 Yan, R. & Vassar, R. Targeting the 0 secretase BACE1 for Alzheimer's disease therapy. The Lancet Neurology 13 (2014 / 03 / 01). https: / / doi. Org / l 0.1016 / S1474~4422(13)70276-X15 Grimm, H. P. et al. Delivery of the Brainshuttle™ amyloid-beta antibody fusion trontinemab to non-human primate brain and projected efficacious dose regimens in humans. inAbs 15 (2023 Oct 12). https: / / doi.org / 10.1080 / 19420862.2023.226150916 Logan, T. et al. Rescue of a lysosomal storage disorder caused by Grn loss of function with a brain penetrant progranulin biologic. Cell 184 (2021 / 09 / 02).17 Colella, P. et al. CNS-wide repopulation by hematopoietic-derived microglia-like cells corrects progranulin deficiency in mice. Nature Communications 202415:1 15 (2024-07-05).18 Sevigny, J. et al. Progranulin AAV gene therapy for frontotemporal dementia: translational studies and phase 1 / 2 trial interim results. Nature Medicine 202430:530 (2024-05- 14). https: / / doi.org / 10.1038 / s41591 -024-02973 -019 Shon, D. J. et al. An enzymatic toolkit for selective proteolysis, detection, and visualization of mucin-domain glycoproteins. Proceedings of the National Academy of Sciences 117 (2020-9-1). https: / / doi.org / 10.1073 / pnas.201219611720 Mirdita, M. et al. ColabFold: making protein folding accessible to all. Nature Methods21 Hanadie Yousef and Cathrin, J. C. a. D. L. a. M. B. C. a. A. N. B. a. K. A. Z. a. J. Z. a. E. B. a. B. Aged blood impairs hippocampal neural precursor activity and activates microglia via brain endothelial cell VCAM1. Nature Medicine 25, 988-1000 (2019).https: / / doi.org / 10.1038 / s41591-019-0440-4
Claims
STDU2-44870.601THE CLAIMSWhat is claimed is:
1. A conjugate comprising a mucin-binding protein or a mucin-binding fragment thereof operably linked to a cargo molecule, wherein the mucin-binding protein or mucin-binding fragment thereof is capable of binding to a mucin-domain glycoprotein on the surface of a brain endothelial cell and mediating internalization of the cargo molecule into the brain endothelial cell.
2. The conjugate of claim 1, wherein the mucin-binding protein or mucin-binding fragment thereof mediates internalization via a caveolae-dependent endocytic pathway.
3. The conjugate of claim 1, wherein the mucin-binding protein or mucin-binding fragment thereof mediates transport of the cargo molecule across the blood-brain barrier.
4. The conjugate of claim 1, wherein the mucin-binding protein or mucin-binding fragment thereof is derived from a bacterial mucinase or an enzymatically inactive variant thereof.
5. The conjugate of claim 4, wherein the bacterial mucinase is secreted protease C (StcE) from Escherichia coli or an ortholog thereof.
6. The conjugate of claim 1, wherein the mucin-binding protein comprises an amino acid sequence having at least about 70% sequence identity to SEQ ID NO:1.
7. The conjugate of claim 6, wherein the mucin-binding protein comprises an amino acid sequence having at least about 80% sequence identity to SEQ ID NO:1.
8. The conjugate of claim 6, wherein the mucin-binding protein comprises an amino acid sequence having at least about 90% sequence identity to SEQ ID NO:1.STDU2-44870.6019. The conjugate of claim 6, wherein the mucin-binding protein comprises an amino acid sequence having at least about 95% sequence identity to SEQ ID NO:1.
10. The conjugate of claim 6, wherein the mucin-binding protein comprises the amino acid sequence of SEQ ID NO:1.
11. The conjugate of claim 1, wherein the mucin-binding fragment comprises the C-terminal domain of StcE or an enzymatically inactive variant thereof.
12. The conjugate of claim 1, wherein the mucin-binding fragment comprises an amino acid sequence having at least about 70% sequence identity to SEQ ID NO:2.
13. The conjugate of claim 12, wherein the mucin-binding fragment comprises an amino acid sequence having at least about 80% sequence identity to SEQ ID NO:2.
14. The conjugate of claim 12, wherein the mucin-binding fragment comprises an amino acid sequence having at least about 90% sequence identity to SEQ ID NO:2.
15. The conjugate of claim 12, wherein the mucin-binding fragment comprises an amino acid sequence having at least about 95% sequence identity to SEQ ID NO:2.
16. The conjugate of claim 12, wherein the mucin-binding fragment comprises the amino acid sequence of SEQ ID NO:2.
17. The conjugate of claim 12, wherein the mucin-binding fragment consists essentially of the amino acid sequence of SEQ ID NO:2.
18. The conjugate of claim 12, wherein the mucin-binding fragment has a molecular weight of about 15 kDa or less.STDU2-44870.60119. The conjugate of claim 1, wherein the mucin-binding protein is a truncated variant of SEQ ID NO:1 comprising the C-terminal domain and lacking one or more domains selected from the group consisting of the immunoglobulin-like (IG) domain, the insertion (INS) region, and the metalloprotease (M) domain.
20. The conjugate of claim 19. wherein the truncated variant lacks the INS region and comprises the IG domain, the M domain, and the C-terminal domain.
21. The conjugate of claim 19, wherein the truncated variant consists essentially of the C-terminal domain.
22. The conjugate of claim 1, wherein the mucin-binding fragment comprises a contiguous amino acid sequence of at least 50 amino acid residues of SEQ ID NO:2 and retains mucindependent binding and internalization activity.
23. The conjugate of claim 22, wherein the mucin-binding fragment comprises at least about 70% of the amino acid residues of SEQ ID NO:2.
24. The conjugate of claim 22, wherein the mucin-binding fragment comprises at least about 80% of the amino acid residues of SEQ ID NO:2.
25. The conjugate of claim 1, wherein the mucin-binding protein or mucin-binding fragment thereof comprises the amino acid sequence of SEQ ID NO:1 or SEQ ID NO:2 with 1 to 20 amino acid substitutions, and wherein the mucin-binding protein or mucin-binding fragment thereof retains mucin-dependent binding and internalization activity.
26. The conjugate of claim 25, wherein the amino acid substitutions are conservative amino acid substitutions.
27. The conjugate of claim 25, wherein the mucin-binding protein or mucin-binding fragment thereof comprises 1 to 10 amino acid substitutions.STDU2-44870.60128. The conjugate of claim 25, wherein the mucin-binding protein or mucin-binding fragment thereof comprises 1 to 5 amino acid substitutions.
29. The conjugate of claim 1, wherein the cargo molecule is selected from the group consisting of a protein, a peptide, an antibody or antigen-binding fragment thereof, an enzyme, a growth factor, a cytokine, a hormone, a nucleic acid, a small molecule, a nanoparticle, a liposome, a viral vector, a detectable label, and a diagnostic agent.
30. The conjugate of claim 1, wherein the cargo molecule is a detectable label selected from the group consisting of a fluorescent protein, a fluorescent dye, a radioactive isotope, a paramagnetic agent, a contrast agent, a quantum dot, and an enzyme that produces a detectable signal.
31. The conjugate of claim 1, wherein the cargo molecule is a diagnostic agent capable of binding to, detecting, or imaging a target molecule in the brain.
32. The conjugate of claim 1, wherein the cargo molecule is a protein having a molecular weight of at least about 10 kDa.
33. The conjugate of claim 1, wherein the cargo molecule is a therapeutic agent.
34. The conjugate of claim 33, wherein the therapeutic agent is an antibody or antigen-binding fragment thereof.
35. The conjugate of claim 34, wherein the antibody or antigen-binding fragment thereof is selected from the group consisting of a monoclonal antibody, a humanized antibody, a fully human antibody, a bispecific antibody, a single-chain variable fragment (scFv). a Fab fragment, a F(ab')2 fragment, a single-domain antibody, and a nanobody.
36. The conjugate of claim 34, wherein the antibody or antigen-binding fragment thereof specifically binds to a target selected from the group consisting of BACE1, amyloid beta, tau,STDU2-44870.601alpha-synuclein, TDP-43, huntingtin, S0D1, PD-L1, CD20, HER2, EGFR, VEGF, and a tumor-associated antigen expressed in the central nervous system.
37. The conjugate of claim 34, wherein the antibody or antigen-binding fragment thereof is an anti-BACE1 antibody.
38. The conjugate of claim 33, wherein the therapeutic agent is a lysosomal protein.
39. The conjugate of claim 38, wherein the lysosomal protein is progranulin or a functional fragment thereof.
40. The conjugate of claim 33, wherein the therapeutic agent is selected from the group consisting of an enzyme replacement therapy protein, a neurotrophic factor, an anti-inflammatory agent, a chemotherapeutic agent, and a gene therapy vector.
41. The conjugate of claim 33, wherein the therapeutic agent is an adeno-associated virus (AAV) vector comprising a transgene encoding a therapeutic protein.
42. The conjugate of claim 33, wherein the therapeutic agent is a nucleic acid selected from the group consisting of an antisense oligonucleotide, a small interfering RNA (siRNA), a short hairpin RNA (shRNA), a microRNA, a messenger RNA (mRNA), a guide RNA, and a ribonucleoprotein complex.
43. A pharmaceutical composition comprising the conjugate of claim 1 and a pharmaceutically acceptable carrier.
44. The pharmaceutical composition of claim 43, formulated for intravenous administration.
45. A method for delivering a cargo molecule across the blood-brain barrier of a subject, comprising administering to the subject a conjugate comprising a mucin-binding protein or a mucin-binding fragment thereof operably linked to the cargo molecule, wherein the mucin-bindingSTDU2-44870.601protein or mucin-binding fragment thereof binds to a mucin-domain glycoprotein on the surface of a brain endothelial cell and mediates transport of the cargo molecule across the blood-brain barrier.
46. The method of claim 45, wherein the conjugate is administered systemically.
47. The method of claim 46, wherein the conjugate is administered intravenously.
48. The method of claim 45, wherein the cargo molecule is delivered to one or more brain cell types selected from the group consisting of brain endothelial cells, neurons, astrocytes, and microglia.
49. The method of claim 45, wherein the cargo molecule is delivered across multiple brain regions.
50. The method of claim 45, wherein the cargo molecule is a detectable label or a diagnostic agent, and the method is for imaging or detecting a target in the brain.
51. The method of claim 45, wherein the conjugate comprises a conjugate of any of claims 1-42.
52. An isolated nucleic acid encoding a fusion protein comprising a mucin-binding protein or a mucin-binding fragment thereof fused to a cargo protein, wherein the mucin-binding protein or mucin-binding fragment thereof comprises an amino acid sequence having at least about 70% sequence identity to SEQ ID NO:1 or SEQ ID NO:2.
53. An expression vector comprising the nucleic acid of claim 52 operably linked to a promoter.
54. A host cell comprising the expression vector of claim 53.STDU2-44870.60155. The host cell of claim 54, wherein the host cell is selected from the group consisting of a bacterial cell, a yeast cell, an insect cell, and a mammalian cell.
56. A method of producing a conjugate for brain delivery, comprising culturing the host cell of claim 54 under conditions sufficient for expression of the fusion protein and recovering the fusion protein from the host cell or culture medium.
57. A kit comprising: (a) a mucin-binding protein or a mucin-binding fragment thereof comprising an amino acid sequence having at least about 70% sequence identity to SEQ ID NO:1 or SEQ ID NO:2; and (b) a linker or conjugation reagent for operably linking the mucin-binding protein or mucin-binding fragment to a cargo molecule of interest.
58. The kit of claim 57, further comprising instructions for conjugating the mucin-binding protein or mucin-binding fragment to a cargo molecule and administering the resulting conjugate to a subject.
59. Use of a conjugate comprising a mucin-binding protein or a mucin-binding fragment thereof operably linked to a cargo molecule for the delivery of the cargo molecule across the bloodbrain barrier, wherein the mucin-binding protein or mucin-binding fragment thereof binds to a mucin-domain glycoprotein on the surface of a brain endothelial cell.
60. The use of claim 59, wherein the mucin-binding fragment comprises an amino acid sequence having at least about 70% sequence identity to SEQ ID NO:2.
61. Use of a conjugate comprising a mucin-binding protein or a mucin-binding fragment thereof operably linked to a therapeutic agent in the manufacture of a medicament for the treatment of a neurological disease or condition, wherein the mucin-binding protein or mucin-binding fragment thereof mediates transport of the therapeutic agent across the blood-brain barrier.
